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Adele Deborah Lenae Crouch 
COGNITIVE DYSFUNCTION IN OLDER BREAST CANCER SURVIVORS 
Up to 75% of the more than 3.5 million breast cancer survivors (BCS) living in 
the United States report cognitive dysfunction. However, little is known about cognitive 
dysfunction among older BCS, who may be at greater risk. Therefore, the purpose of this 
dissertation was to characterize cognitive dysfunction in older BCS. Specific aims 
included:  
(1) synthesize the literature regarding cognitive dysfunction in older BCS; and 
(2) examine the relationships between a) objective cognitive function (immediate 
memory, delayed memory, attention, executive function-working memory, verbal 
fluency) and subjective cognitive function (attention); b) demographic factors, medical 
factors, treatment factors, and cancer-related symptoms (depressive symptoms, anxiety, 
fatigue, sleep disturbance) and cognitive function; and c) comorbidity and cognitive 
function and physical functioning, and quality of life (QoL) in older BCS.   
In an integrative review, to address aim 1, 12 studies were identified. Up to 41% 
of older BCS showed objective cognitive dysfunction on neuropsychological assessment, 
up to 64% reported subjective cognitive dysfunction concerns pre-treatment, and 50% 
incurred cognitive decline from pre- to post-treatment. Cognitive dysfunction was 
associated with older age, multiple comorbidities, chemotherapy, sleep disturbance, 
neuropsychological symptom cluster, frailty, and poorer QoL. 
To address aim 2, data were leveraged from a large, nationwide, QoL in younger 
versus older BCS study (PI: Champion), which included 335 older BCS who were ≥60 
years of age, had breast cancer (stage I-IIIa), received chemotherapy, and were 3-8 years 
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post-diagnosis without recurrence. Findings included up to 19% of older BCS had mild-
moderate objective cognitive dysfunction on at least one neuropsychological assessment, 
with 26% reporting poor-moderate subjective attention function. BCS, who were older, 
had less education and more depressive symptoms had greater cognitive dysfunction. 
Objective attention and executive function-working memory significantly and positively 
correlated with subjective attention. In turn, subjective cognitive dysfunction and 
increased number of comorbidities were related to poorer physical functioning. 
Subjective cognitive dysfunction was also related to poorer QoL. The findings from this 
study highlights the prevalence and complexity of cognitive dysfunction in older BCS. 
Further research is needed to better understand the intersection of aging, cancer, 
comorbidities and cognitive dysfunction and the negative implications in older BCS. 
Diane Von Ah, PhD, RN, FAAN, Chair 
  
viii 
TABLE OF CONTENTS 
 
LIST OF TABLES ............................................................................................................. xi 
LIST OF FIGURES  ......................................................................................................... xii 
LIST OF ABBREVIATIONS .......................................................................................... xiii 
CHAPTER 1 ........................................................................................................................1 
Background and Significance ........................................................................................1 
Purpose, Specific Aims, and Research Questions .........................................................4 
Conceptual Framework ..................................................................................................5 
Approach ........................................................................................................................7 
Research Design.......................................................................................................7 
Eligibility Criteria ....................................................................................................7 
Recruitment ..............................................................................................................8 
Sample......................................................................................................................8 
Data Collection and Management ............................................................................9 
Measures ................................................................................................................10 
Demographic, Medical, and Treatment Factors ...............................................10 
Depressive Symptoms ......................................................................................10 
Anxiety .............................................................................................................10 
Fatigue..............................................................................................................11 
Sleep Disturbance ............................................................................................11 
Immediate and Delayed Memory.....................................................................11 
Attention and Executive Function-Working Memory .....................................12 
Verbal Fluency .................................................................................................12 
Subjective Attention.........................................................................................13 
Physical Function .............................................................................................13 
Quality of Life..................................................................................................13 
Data Analysis .........................................................................................................14 
Sample Size and Power Analysis ...........................................................................16 
Conclusion ...................................................................................................................16 
CHAPTER 2 ......................................................................................................................21 
Introduction  .................................................................................................................21 
Methods........................................................................................................................22 
Eligibility Criteria ..................................................................................................23 
Literature Search ....................................................................................................24 
Data Extraction and Analyses ................................................................................24 
Results ..........................................................................................................................25 
Search Results ........................................................................................................25 
Study Characteristics .............................................................................................26 
Objective Cognitive Dysfunction ................................................................................27 
Prevalence ..............................................................................................................27 
Associated Factors .................................................................................................28 
Demographic ....................................................................................................28 




Quality of Life..................................................................................................31 
Subjective Cognitive Dysfunction ...............................................................................31 
Prevalence ..............................................................................................................31 
Associated Factors .................................................................................................32 
Demographic ....................................................................................................32 
Medical and Treatment ....................................................................................32 
Cancer-Related Symptoms...............................................................................33 
Physical/Functional ..........................................................................................34 
Quality of Life..................................................................................................34 
Discussion ....................................................................................................................34 
Strengths and Limitations ......................................................................................40 
Implications for Future Research ...........................................................................40 
Implications for Oncology Nursing Practice .........................................................41 
Conclusion ...................................................................................................................42 
CHAPTER 3 ......................................................................................................................52 
Introduction ..................................................................................................................52 
Methods........................................................................................................................54 
Population and Data Collection .............................................................................55 
Measures ................................................................................................................56 
Demographic, Medical, and Treatment Factors ...............................................56 
Cancer-Related Symptoms...............................................................................56 
Objective Cognitive Function ..........................................................................57 
Subjective Cognitive Function .........................................................................58 





CHAPTER 4 ......................................................................................................................76 
Introduction  .................................................................................................................76 
Methods........................................................................................................................77 




Objective Cognitive Function ..........................................................................78 
Subjective Cognitive Function .........................................................................79 
Physical Functioning ........................................................................................79 
Quality of Life..................................................................................................79 
Data Analysis .........................................................................................................80 
Results ..........................................................................................................................80 
Physical Functioning ..............................................................................................81 
Quality of Life........................................................................................................83 
Discussion ....................................................................................................................83 
Limitations .............................................................................................................85 
Conclusion  ..................................................................................................................86 
x 
CHAPTER 5 ......................................................................................................................92 
Introduction  .................................................................................................................92 
Summary of Key Findings ...........................................................................................93 
Chapter 2 ................................................................................................................93 
Chapter 3 ................................................................................................................94 
Chapter 4 ................................................................................................................95 








LIST OF TABLES 
 
Table 1-1 Summary of Study Measures.............................................................................18 
Table 1-2 Power Estimates for a Multiple Regression Analysis Model  ...........................20 
Table 2-1 Articles Examining Cognitive Dysfunction in Older Breast Cancer  
Survivors ............................................................................................................................44 
Table 2-2 Factors Associated with Subjective or Objective Cognitive Dysfunction in 
Older Breast Cancer Survivors ..........................................................................................50 
Table 3-1 Sample Characteristics ......................................................................................69 
Table 3-2 Cancer-Related Symptoms and Measures - Mean (SD), Potential Range,  
and Actual Range ...............................................................................................................70 
Table 3-3 Objective Cognitive Measures and Dysfunction by Domain ............................71 
Table 3-4 Subjective Attention Function Measure and Dysfunction .................................73 
Table 3-5 Cognitive Measure Bivariate Correlations ........................................................74 
Table 3-6 Regression Analysis Summary for Demographic, Medical, and Treatment 
Factors, Cancer-Related Symptoms, and Cognitive Function Measures ...........................75 
Table 4-1 Self-reported Comorbid Conditions ..................................................................87 
Table 4-2 Outcome Variables and Measures - Mean (SD), Potential Range, and  
Actual Range ......................................................................................................................88 
Table 4-3 Regression Analysis Summary for Age, Education, Comorbidities,  





LIST OF FIGURES 
 
Figure 1-1 Conceptual Framework for Dissertation ..........................................................17 
Figure 2-1 Preferred Reporting Items for Systematic Reviews and Meta-analysis 







LIST OF ABBREVIATIONS 
 
BCS Breast Cancer Survivor 
QoL Quality of Life 
IU Indiana University 
ECOG Eastern Cooperative Oncology Group 
IRB Institutional Review Board 
NCC Non-Cancer Control 
SD Standard Deviation 
CESD Center for Epidemiologic Studies Depression 
STAI State-Trait Anxiety Inventory 
FACT-F Functional Assessment of Cancer Therapy: Fatigue 
PSQI Pittsburg Sleep Quality Index 
AVLT Rey Auditory-Verbal Learning Test 
WAIS Wechsler Adult Intelligence Scale 
COWA Controlled Oral Word Association 







Background and Significance 
 Breast cancer survivors (BCS) make up the largest group of cancer survivors with 
approximately 3.5 million BCS living in the United States alone [1]. Of those BCS, over 
60% are 60 years of age and older and that number is expected to grow as society 
continues to age [2-7]. Advances have been made in detection, earlier diagnosis, and 
improved treatment of breast cancer including precision health and targeted therapeutics, 
which has contributed to increased long-term survival [2]. In fact, breast cancer mortality 
rates have decreased steadily and rapidly from 1989 to 2015 with a total decrease of 39% 
[1]. Relative survival rates have increased and are now at 91% at 5-years after diagnosis, 
86% after 10-years, and 80% after 15-years [1]. As the expected survival from breast 
cancer lengthens and age expectancy of the nation’s population increases, older BCS 
(≥60 years of age) represent the largest population in the cancer survivor community [5]. 
BCS incur a myriad of physical, psychological, social, and cognitive symptoms resulting 
from their breast cancer diagnosis and treatment that can persist into survivorship [8].  
One symptom BCS may incur after cancer diagnosis and treatment is cognitive 
dysfunction. Cognitive dysfunction includes both objective cognitive dysfunction 
measured by performance on neuropsychological assessments and subjective cognitive 
dysfunction or self-reported concerns by BCS. Cognitive dysfunction is a prevalent, 
bothersome, and potentially debilitating problem for many BCS following chemotherapy 
treatment. Research has shown that up to 75% of all age BCS report cognitive 
dysfunction, including concerns of forgetfulness or recalling information, problems with 
processing information and multi-tasking, and/or difficulties problem-solving after cancer 
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treatment [1,2,4,9-12]. Meta-analyses also support the prevalence of objective cognitive 
dysfunction, including primarily deficits in memory, speed of processing, and executive 
function in all age BCS [13,14]. However, none of the published meta-analyses and very 
limited studies to date have focused on older BCS. With the aging population and 
increased survival rates, more research is needed to understand and characterize both 
objective and subjective cognitive dysfunction in older BCS, the largest cancer survivor 
group [2].  
Older BCS may be at a greater risk of suffering from cognitive dysfunction after 
breast cancer diagnosis and treatment with chemotherapy. Older BCS were defined as 
women who were diagnosed with breast cancer and who were 60 years of age and older 
at the time of diagnosis. This definition coincides with the definition used in the Older 
Americans Act and the Centers for Disease Control report for identifying vulnerable 
older adults [15]. Focusing on older BCS in this age group is important because they 
make up the majority of new breast cancer cases, are the largest sub-population of BCS, 
and older BCS are believed to be more susceptible to cognitive dysfunction [16,17].  
Older BCS may be at an increased risk for cognitive dysfunction after breast 
cancer diagnosis and treatment due to a number of factors, including the normal aging 
process, pre-existing conditions or comorbidities, the neurotoxic effects of chemotherapy 
treatments and/or a combination of these factors [3,15-24]. Normal aging is often 
associated with some cognitive decline and thus, older BCS may have lower baseline 
cognitive reserve prior to chemotherapy treatment, placing them at greater risk for 
cognitive dysfunction. In fact, a study by Ahles and colleagues (2010) demonstrated that 
older age, chemotherapy exposure, and lower cognitive reserve are associated with 
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increased cognitive dysfunction among a group of all age BCS [3,25]. Chemotherapy has 
also been shown to have neurotoxic effects. Researchers have established that BCS who 
received chemotherapy may have both structural (white and gray matter changes) and 
functional changes, which have been related to both objective and subjective cognitive 
dysfunction in the literature [26-29]. In fact, chemotherapy has been hypothesized as 
accelerating the effects of aging, as both are associated with similar biologic changes 
including DNA damage, oxidative stress, inflammation, and shortened telomere length 
[3,30,31]. This accelerated aging process, in turn, may hasten cognitive decline in some 
BCS, especially older BCS [3]. Thus, older BCS who receive chemotherapy may be at an 
increased risk for cognitive dysfunction; however, more research is needed to address this 
at risk population [3].  
Despite the fact that cognitive dysfunction is receiving more attention, researchers 
have continued to focus on all age BCS. Less is known about cognitive dysfunction 
among older BCS (women diagnosed with breast cancer who are 60 years of age and 
older). Most of the research regarding cognitive dysfunction has been conducted with all 
age BCS. Thus, there is a need to both conduct a thorough review of this literature and 
conduct more research to fully characterize cognitive dysfunction in older BCS in order 
to develop interventions.   
The existing literature regarding cognitive dysfunction in BCS has been limited 
by varying definitions and measures of cognitive dysfunction, with most studies failing to 
include measures of both objective and subjective cognitive function. Although, objective 
cognitive assessments have been identified as the ‘gold standard,’ subjective or self-
reported cognitive concerns are often the first indication of cognitive dysfunction and 
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have been hypothesized to represent more subtle changes following treatment [10,32,33]. 
Therefore, it is essential to measure both to fully characterize cognitive dysfunction, as 
well as, to determine if these measures are associated.  
It is also critical to elucidate factors that characterize older BCS with cognitive 
dysfunction so evidence-based interventions can be developed to improve cognitive 
dysfunction, and ultimately improve quality of life (QoL). Research has shown that 
demographic factors (age and education), medical factors (comorbidities), and treatment 
factors (time since diagnosis and breast cancer stage) may be related to cognitive 
dysfunction; however, research has been mixed [23,24,34]. Cancer-related symptoms 
(depressive symptoms, anxiety, fatigue, and sleep disturbance) have also been 
prominently reported and linked to cognitive dysfunction in all age BCS; [35-38] 
however, only a few studies have examined this relationship in older BCS, and results 
have been equivocal [23,24,39].  
Cognitive dysfunction may also be related to decreased physical functioning and 
QoL, which is important to understand, especially in older BCS [23,34,39-43]. The 
paucity of research regarding cognitive dysfunction in older BCS demonstrates a 
significant gap in knowledge and with the rapidly aging population represents a 
significant challenge in providing quality cancer care in the future [44-49].  
Purpose, Specific Aims, and Research Questions 
Overall, the purpose of this dissertation study was to fully characterize cognitive 
dysfunction in older (≥60 years old) BCS. Specific aims are to: 
Aim 1: Synthesize the literature regarding cognitive dysfunction in older BCS. 
Specifically, examine the prevalence of cognitive dysfunction in older BCS, 
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including both objective and subjective measures and examine factors associated 
with these measures of cognitive dysfunction. 
Aim 2: Examine the relationships:  
a) between objective cognitive function (immediate and delayed memory, 
attention, executive function-working memory, and verbal fluency) and 
subjective cognitive function (subjective attention); 
b) between demographic, medical, treatment factors, and cancer-related 
symptoms (depressive symptoms, anxiety, fatigue, and sleep disturbance) 
and objective cognitive function and subjective cognitive function; and 
c) between comorbidities, objective cognitive function, and subjective 
cognitive function and physical functioning and QoL, in older BCS. 
This dissertation will address the following research questions illustrated in 
Figure 1-1 including: (1) What do we currently know regarding cognitive dysfunction 
among older BCS? (2) Are there relationships between objective measures and subjective 
measure of cognitive function among older BCS? (3) Are demographic factors, medical 
factors, treatment factors, and cancer-related symptoms related to objective and 
subjective cognitive function among older BCS? (4) Are comorbidities and objective and 
subjective cognitive function related to physical functioning and QoL among older BCS? 
Conceptual Framework 
The guiding conceptual framework for this study, which is congruent with the 
parent study, was derived and modified from Hess and Insel’s (2007) Conceptual Model 
of Cancer-Related Changes in Cognitive Function and from the relevant literature (see 
Figure 1-1) [50]. The model examines the physiologic and psychological factors 
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(antecedents and consequences) related to cancer-related changes in cognitive function 
and provides a rational framework. The model depicts that certain demographic, medical, 
and treatment factors, and cancer-related symptoms are linked with cognitive dysfunction 
and that cognitive dysfunction following cancer diagnosis and treatment is related to 
untoward outcomes or consequences including poorer quality of life and functional 
ability. The framework for this dissertation study draws on those hypothesized 
relationships by examining some of those same factors in association with objective and 
subjective cognitive dysfunction in older BCS specifically. Cognitive dysfunction is 
conceptually defined as a complex symptom identified by cognitive changes that 
negatively affect or alter higher-order mental processes, including but not limited to 
memory (immediate and delayed), attention, executive functioning-working memory, and 
verbal fluency [50,51]. In this model and the BCS literature, cognitive dysfunction is 
operationally defined by both objective and subjective assessments. 
Based on the model and the review of literature, the relationship between 
objective and subjective cognitive function in older BCS was examined (Aim 2a). 
Demographic (age and education), medical (number of comorbidities), and treatment 
factors (time post diagnosis and breast cancer stage), and cancer-related symptoms 
(depressive symptoms, anxiety, fatigue, and sleep disturbance) are included in the model 
and will be examined in relationship with both objective and subjective cognitive 
function (Aim 2b) [23,24,34,39]. The model also depicts two potential related sequelae of 






Data for this descriptive, secondary data analysis, dissertation study were 
leveraged from a large, nationwide, American Cancer Society funded-study (RSGPB-04-
089-01, PI: Champion) aimed at understanding the unique needs of younger BCS by 
comparing the QoL of younger BCS to older BCS [52]. Data are from a cross-sectional 
study in which female BCS who were 3-8 years post-diagnosis completed mailed 
questionnaires and neuropsychological assessments conducted reliably via telephone 
[53]. This study reports on the objective and subjective cognitive data that was not 
reported or published from the original study.  
Eligibility Criteria 
Inclusion criteria and rationale for this dissertation study included: 1) female 
gender (breast cancer is rare in men <1% of new diagnoses), 2) 60 years of age and older 
at diagnosis, 3) 3-8 years from initial diagnosis without a breast cancer recurrence (BCS 
expressed time of most concern when life should be back to normal; and to avoid 
confounding factors related to reoccurrence/more homogenous sample), 4) stage I-IIIa at 
diagnosis (to control for brain metastasis/avoid those with previous use of cranial 
radiation therapy or intrathecal therapy), 5) able to read and write English (to enable 
informed consent/participation), 6) received chemotherapy (Adriamycin, Paclitaxel, and 
Cyclophosphamide) as part of their initial treatment (most at risk for cognitive 





Human subjects protection was obtained for the parent study from Indiana 
University (IU) institutional review board (IRB) and from the local IRB at each of the 
cooperating sites. Initially, the statistical office for ECOG identified BCS who met 
eligibility criteria and forwarded the names to the BCS’s treating physician. The 
physician or designee contacted the BCS and asked for permission to forward their name 
and contact information to researchers at IU. If BCS gave permission for contact, the 
identifying information for each BCS was sent to researchers. IU then mailed the BCS a 
brochure explaining the study. One week following this initial mailing, research staff 
called the BCS to answer any questions and determine interest in participation. If verbal 
consent was obtained, the BCS was mailed the written informed consent and 
questionnaire with postage-paid return envelopes. A date was then set for the telephone 
interview and neuropsychological assessment. Follow-up reminder telephone calls were 
made if the survey and informed consent were not received within two weeks. If a 
participant could not be reached by phone and did not return the consent after 10 phone 
attempts, they were not contacted again. 
Sample 
In the parent study, younger BCS (age < 45) and older BCS (age 55-70) were 
approached from Indiana University (IU) and Eastern Cooperative Oncology Group 
(ECOG) 97 sites, as described in recruitment procedures. Of those BCS approached, a 
sample of 505 younger BCS and 622 older BCS were recruited and determined to be 
eligible and consented to the study. This dissertation study only focuses on older BCS; 
therefore, of the 622 older BCS who were eligible and verbally consented, 491 (79%) 
9 
completed and returned study materials including written consent and survey 
questionnaires. Of those 491 who completed all study materials, 335 (68%) were 60 years 
of age or older at the time of diagnosis and had completed both the survey questionnaires 
and objective neuropsychological assessments. Therefore, for this dissertation study, a 
total of 335 older (≥60 years of age) BCS with complete data were eligible and included 
in this study. 
Data Collection and Management 
In the parent study, data was collected primarily by self-report surveys. Trained 
research assistants then de-identified and entered the data in a password protected 
database. Neuropsychological assessments were performed by trained staff via the 
telephone under the direction of a licensed psychologist, expert in neuropsychological 
assessments, and study coinvestigator. Neuropsychological assessments delivered via the 
telephone have been found to be reliable and comparable to in-person assessment [53]. 
Participants received $25 for completing the survey packet and $25 for completing the 
neuropsychological assessment. To ensure the quality of each neuropsychological 
assessment the examiner assessed the subject’s hearing, comprehension, behavioral and 
attitudinal responses, telephone connection, extraneous noises, interruptions, and/or 
abnormal events [53]. The parent study and the resulting data were monitored for quality, 
recruitment, accrual and retention, outcome and adverse events, and procedures were 
audited to ensure subject confidentiality. Questionnaires were coded with an 
identification number so that individuals can only be identified by linking the 
identification number with the participant list. The participant list for the parent study 
was secured in a separate password protected database with limited accessibility. For this 
10 
dissertation study, all electronic data were de-identified and stored on secure password 
protected, HIPAA compliant drive accessible only to investigators.  
Measures 
All assessment measures used in this study are reliable and valid and have been 
used with BCS. Table 1-1 displays the variables, measures used, number of items, 
potential score range, reliability of each measure, and scoring interpretation. Most of the 
neuropsychological assessments have been recommended by the International Cancer and 
Cognition Task Force and/or are part of the National Institutes of Health toolbox. In the 
following section, all instruments used in this study will be reviewed [53,54]. 
Demographic, Medical, and Treatment Factors. Demographic, medical, and 
treatment data were collected via investigator-initiated questionnaire (self-report) and 
medical record. Information included age at diagnosis and current age at data collection, 
race/ethnicity, education, income, marital status, number of comorbidities, specific 
comorbid conditions, breast cancer diagnosis date and stage, and cancer treatment 
(surgery, radiation).  
Depressive Symptoms. The Center for Epidemiologic Studies Depression Scale 
(CES-D) is a 20-item instrument used to assess the presence and severity of depressive 
symptoms over the past week. Total scores range from 0 to 60, with higher score 
indicating more depressive symptoms [55,56]. The CES-D has shown satisfactory 
validity and reliability in the literature and has been widely used in cancer patients 
including BCS [55-57]. In this study, the Cronbach alpha was .84.  
Anxiety. The Spielberger State-Trait Anxiety Inventory (STAI) state subscale is a 
20-item instrument assessing state anxiety, or how the participant feels currently on a 4-
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point scale ranging from 1 (not at all) to 4 (very much so). Total scores range from 20 to 
80, with higher scores indicating more anxiety [58]. This STAI has been established as 
both valid and reliable and has been widely used in cancer patients including BCS and 
has been used in previous cognitive studies with BCS [23,39,58]. In this study, the 
Cronbach alpha was .93.   
Fatigue. The Functional Assessment of Cancer Therapy-Fatigue (FACT-F) is a 
13-item measure that asks respondents to rate symptoms of fatigue over the last four 
weeks on a 5-point scale ranging from 0 (not at all) to 4 (very much so) [59]. Total scores 
range from 0-52 with higher scores indicating more fatigue. The FACT-F was designed 
and validated for cancer patients, has strong psychometric properties, and has been used 
extensively with BCS [59]. In this study, the Cronbach alpha was .93.  
Sleep Disturbance. The Pittsburgh Sleep Quality Index (PSQI) sleep disturbance 
subscale is a 9-item measure used to assess sleep disturbances during the past four weeks 
[60]. Potential scores range from 0 to 3, with higher scores indicating poorer sleep or 
more sleep disturbance [60]. This measure has been used previously among BCS and had 
acceptable reliability (Cronbach alpha .70-.80) [38,61,62]. In this study, the Cronbach 
alpha was .68.  
Immediate and Delayed Memory. The Rey Auditory Verbal Learning Test 
(AVLT) is a word list reading task that is used to test immediate and delayed memory 
[63]. Participants are presented with a 15-item word list for five learning trials. 
Immediate recall is taken after each trial. Delayed recall of the initial list is taken 30-
minutes later after other assessments have been completed. The immediate memory score 
is the total number of words recalled all five learning trials, with higher scores indicating 
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better performance. The delayed memory is the total number of words the individual 
remembers from the initial list after the 30-minute delay, with higher scores indicating 
better performance. The AVLT has good test-retest reliability r=.77 (immediate) and 
r=.60 (delayed) and has been used in BCS [63-66]. 
Attention and Executive Function-Working Memory. The Wechsler Adult 
Intelligence Scale IV (WAIS) - Digit Span Forward and Backward is used to assess 
attention and executive function-working memory, respectively [67]. The subscales of the 
Digit Span Forward (attention) and Backward (executive function-working memory) will 
be reported separately as two different cognitive domains in this study. Digit Span-
Forward specifically assesses attention. For the Digit Span-Forward test, the tester 
verbalizes a string of digits and the participant must recite the digit string in the same 
order it is given. Digit Span-Backward specifically assesses executive function-working 
memory. For the Digit Span-Backward test, the tester verbalizes a string of digits and the 
participant must recite the digit string reversing the order. Digit Span uses verbal 
repetition of digit strings forward and backward that gradually get longer. The score for 
Forward and Backward separately is the number of digit strings correctly recited with 
higher scores indicating better functioning. The Digit Span-forward and backward have 
good test-retest reliability r=.89 and r=.83, respectively [67,68].  
Verbal Fluency. The Benton Controlled Oral Word Association Test (COWA) is 
designed to evaluate the spontaneous production of words beginning with a given letter 
(e.g. C, F, L) within a limited amount of time. Participants are asked to produce as many 
words they can think of that begin with the given letter, excluding proper nouns and the 
same word with a different suffix, in one minute [69]. This instrument is used to assess 
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verbal fluency, with higher scores indicating better functioning. The COWA has good 
test-retest reliability r=.70 and has been previously used in BCS [70].  
Subjective Attention. Subjective cognitive function (subjective attention) was 
measured using the Attentional Function Index (AFI), a 13-item self-report instrument 
used to assess perceived effectiveness in common activities requiring attention, working 
memory, and executive function on a 0-10 scale, with potential scores ranging from 0-
130 [71]. High scores on this instrument indicate better perceived attention function. 
There are predetermined cut-points used in the literature to indicate level of functioning; 
<50 indicates low/poor attention function, 50-70 indicated moderate attention function, 
and >75 indicated good attention function [71]. In this study, the Cronbach alpha was .80.  
Physical Function. The Physical Functioning-10 (PF-10) is a subscale of the 
Medical Outcomes Study 36-item Short Form Health Survey (SF-36) [72, 73]. The SF-
36, and its subscales including the PF-10, have been established as a comprehensive 
measure of general health that has shown reliability and validity in various populations, 
including cancer patients [72]. The PF-10 measures the participants perceived limitations 
of physical functioning during the past four weeks with a 3-point scale (yes, limited a lot; 
yes, limited a little; and no, not limited at all), using the original 0-100 scoring with 
higher scores indicating less limitation or disability [73]. In this study, the PF-10 subscale 
had a Cronbach alpha of .89.  
Quality of Life. The Index of Well-Being–Survivor (IWB) is a 9-item measure 
used to assess QoL at present time, by asking how the individual feels about their life on 
a 7-point semantic differential scale, from 1 (boring) to 7 (interesting); 1 (useless) to 7 
(worthwhile); or 1 (enjoyable) to 7 (miserable), and so on [74]. Scores range from 2.1 to 
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14.7, with higher scores indicating better QoL. This instrument was developed to 
measure specific concerns of long-term cancer survivors, including BCS, and has 
established reliability and validity [52,73,75]. In this study, the Cronbach alpha was 0.92.  
Data Analysis 
For this dissertation study, a dataset was created from the database of the parent 
study. IRB approved data managers retrieved the cases from the original databases that 
match eligibility criteria. A sample size of 335 BCS who are ≥ 60 years of age and met 
all eligibility criteria with objective cognitive function data were included. Descriptive 
statistics appropriate for the measurement level (e.g., frequencies and percentages for 
nominal/ordinal; mean and standard deviation for interval/ratio) were computed for all 
variables to ensure data quality, identify out of range values, and evaluate the 
assumptions of statistical tests including normality and intercorrelation of independent 
variables and were also be used to describe the sample. Specific data analyses for each 
aim are presented as follows: 
Aim 1: Synthesize the literature regarding cognitive dysfunction in older BCS. 
Specifically, examine the prevalence of cognitive dysfunction in older BCS, 
including both objective and subjective measures and examine factors associated 
with these measures of cognitive dysfunction. 
Analysis for Aim 1: The literature will be reviewed and synthesized using Whittemore 
 and Knafl integrative review methods [76]. 
Aim 2a: Examine the relationships between objective cognitive function and subjective 
cognitive function in older BCS. 
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Analysis for Aim 2a: Pearson correlation (r) will be used to examine the relationships 
between objective cognitive functioning (immediate and delayed memory, 
attention, executive function-working memory, and verbal fluency) and subjective 
cognitive functioning (subjective attention). 
Aim 2b: Examine demographic, medical, and treatment factors, and cancer-related 
symptoms and their relationship with objective cognitive function and subjective 
cognitive function in older BCS. 
Analysis for Aim 2b: Separate multiple linear regressions were computed to examine the 
relationships between independent variables of demographic (age and education), 
medical (number of comorbidities), and treatment factors (time since diagnosis 
and breast cancer stage), and cancer-related symptoms (depressive symptoms, 
anxiety, fatigue, and sleep disturbance) and dependent variables of objective 
cognitive function (immediate and delayed memory, attention, executive function-
working memory, and verbal fluency) and subjective cognitive function 
(attention) in older BCS.  
Aim 2c: Examine comorbidities, objective cognitive function and subjective cognitive 
function and their relationship with physical functioning and QoL in older BCS. 
Analysis for Aim 2c: Separate multiple linear regressions were computed to examine the 
relationship between independent variables of age, education, comorbidities, 
objective cognitive function (immediate and delayed memory, attention, executive 
function-working memory, and verbal fluency) and subjective cognitive function 
(attention) and dependent variables of physical functioning and QoL in older 
BCS. 
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Sample Size and Power Analysis  
The power analysis was based on the statistical approach described above. Table 
1-2 below shows power estimates for a performing a linear regression model with 
continuous variables. Effect size estimates (small, medium and large) were chosen from 
Cohen (2013) [77]. These effect sizes correspond to estimating a model with an R2 value 
of 2% (small), 13% (medium) and 26% (large). Analysis shows the sample of 335 
subjects will have sufficient power to detect both medium and large effect sizes for any 
regression model ranging from one to ten independent variables. The table also shows the 
smallest effect size (between small and medium) where all possible models will have at 
least 80% power. This corresponds to an effect size of f2 = 0.05 or R2 value of 5%. 
Conclusion 
 The overall purpose of this dissertation was to characterize cognitive dysfunction 
in older BCS. The following chapters will systematically address the aims of the 
dissertation. Findings from this work will be used to identify older BCS at risk for 
cognitive dysfunction as well as identify potential interventions to address cognitive 
dysfunction in older BCS.   
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Figure 1-1 Conceptual Framework for Dissertation  
 
Note: This conceptual framework is congruent with the parent study [52] and was derived 
and modified from Hess and Insel’s (2007) Conceptual Model of Cancer-Related 
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Table 1-2 Power Estimates for a Multiple Regression Analysis Model 
 Number of independent variables 
Effect size 1 2 5 7 10 
Small: 
f2=0.02, 
R2 = 0.02 





R2 = 0.05 
0.98 0.96 0.90 0.86 0.80 
Medium: 
f2=0.15, 
R2 = 0.13 
0.99 0.99 0.99 0.99 0.99 
Large: 
f2=0.35, 
R2 = 0.26 
1.00 1.00 1.00 1.00 1.00 
 
Note: (N=335); alpha level set to 0.05; R2 = percent variance explained by model; f2 = 





Older breast cancer survivors (BCS) (60 years of age and older) make up 
approximately 60% of the more than 3.8 million BCS living in the United States, and this 
number is projected to rise as the nation’s population continues to age [17,79,80]. 
Although some studies suggest that older cancer survivors may be more equipped to deal 
with the psychological symptoms and burden of a cancer diagnosis and treatment; [80] 
most studies report that older survivors may have a greater risk for experiencing 
potentially debilitating side-effects [81-83]. Older BCS may be at an increased risk for 
developing cognitive dysfunction following cancer diagnosis and treatment due to the 
normal neurodegenerative effects of aging and the neurotoxic effects of cancer treatment, 
which has both direct effects as well as has been hypothesized to accelerate the aging 
process [3,84]. 
Cognitive dysfunction has been recognized as a prevalent and distressing problem 
in the BCS of all ages [4,64]. Researchers have documented up to 75% of BCS report 
cognitive dysfunction, however, less is known regarding cognitive dysfunction in older 
BCS. Researchers are beginning to recognize that older cancer patients may have unique 
needs and consequences of cancer related cognitive dysfunction. In fact, a recent position 
paper by Pergolotti and colleagues (2019) highlighted the needs and consequences older 
cancer patients may face including comorbidities, polypharmacy, frailty, changes in level 
of independence, functional and physical abilities, decision making capacity, as well as 
an increased likelihood of dementia [84,85]. There are many gaps in knowledge 
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regarding cognitive dysfunction in the older cancer patient population and a critical need 
for further research to better understand the complexity of the problem [84].  
Therefore, the purpose of this integrative literature review was to 
comprehensively examine cognitive dysfunction in older (60 years of age and older) 
BCS. Specifically, this review examined the prevalence of cognitive dysfunction in older 
BCS, including both objective and subjective self-report measures. Additionally, factors 
associated with these measures of cognitive dysfunction were also examined. Findings 
from this review elucidated the problem of cognitive dysfunction in older BCS and 
identify potential modifiable factors that may be associated with cognitive dysfunction in 
older BCS, which in turn, potentially informing the future development of evidence-
based treatment and care for cognitive dysfunction in older BCS specifically. 
Methods 
An integrative review was conducted to summarize literature regarding the 
prevalence of cognitive dysfunction and factors associated with cognitive dysfunction in 
older BCS.  The Whittemore and Knafl integrative review method was used as it allows 
for multiple diverse research designs and methods and includes: 1) problem 
identification, 2) literature search, 3) data evaluation, 4) data analysis, and 5) presentation 
of findings [76]. For this review, cognitive dysfunction was defined as a cognitive change 
that negatively affects high-order mental processes, including executive function, 
attention, concentration, intelligence, memory, recall, psychomotor ability, processing, 
verbal ability, vigilance, visuospatial and visuomotor ability [51,50]. Cognitive function 
may be measured using objective neuropsychological exam and/or subjective self-report 
measures and both were included in this review. 
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Eligibility Criteria 
Manuscripts included in this review were empirical studies, published in English 
between 2006 and 2019 in peer-reviewed journals, and included older (60 years of age 
and older) breast cancer survivors. Older BCS were defined as women with a breast 
cancer diagnosis who were 60 years of age and older. This definition uses 60 years of age 
and older, which is congruent with the Centers for Disease Control and federal Older 
American Act criteria [15]. This review importantly focused on older BCS in this age 
group, because they make up the majority of new breast cancer cases, are the largest sub-
population of BCS, and older BCS are believed to be more susceptible to cognitive 
dysfunction [16,17]. Studies included in the review were also required to have reliable 
and valid measure(s) of cognitive dysfunction including objective and/or subjective 
assessments. Both objective and subjective assessments of cognitive dysfunction are 
important to the overall understanding of cognitive dysfunction in older BCS. Objective 
neuropsychological assessments are comprised of performance-based tests to assess 
various cognitive skills and function and are often considered the gold standard for 
assessing cognitive dysfunction [54,86]. Subjective assessments, including self-report 
measures of cognitive dysfunction, are also important to identifying cognitive 
dysfunction in the clinical setting, are often used as the initial indication for referrals for 
more in-depth neuropsychological assessments, and have been used in the larger BCS 
literature to identify subtle indicators of cognitive dysfunction that is not always detected 
on neuropsychological exam [9,33,87].  
Studies were excluded that focused solely on breast cancer survivors with 
metastatic disease to avoid confounding those with brain metastasis and/or those with 
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previous use of cranial radiation therapy or intrathecal therapy. In addition, studies with a 
sole focus on dementia were excluded, as articles examining potentially modifiable 
associated factors of cognitive dysfunction were of most interest.  
Literature Search 
Databases used in this review included: PubMed, the Cumulative Index to 
Nursing and Allied Health Literature - CINAHL, PsycINFO, MEDLINE, and Web of 
Science. These databases were chosen based upon the subject areas they encompass 
including nursing, medicine, allied health, and psychology. Data bases were searched for 
relevant manuscripts from 2004 to 2019 to include literature published over the past 15 
years. To capture the older BCS population with cognitive dysfunction, search terms 
alone and in combination included: “breast cancer,” “breast cancer survivor,” “breast 
cancer survivorship,” “cognitive impairment,” “cognitive dysfunction,” “older,” 
“elderly,” “geriatrics,” and “seniors.”  
Data Extraction and Analyses 
Each article was reviewed by two authors (A.C. and D.V.) to ensure appropriate 
study inclusion, exclusion, and data extraction. Data from the included studies was 
extracted, organized, confirmed and displayed in tables. Table 2-1 displays information 
from each study including: first-author name, publication date, population (n), study 
design, trajectory (Pre-, During-, and Post-treatment), prevalence of cognitive 
dysfunction, and factors associated with cognitive dysfunction. Table 2-2 denotes all of 
the factors examined and which factors were significantly related to either subjective 





Figure 2-1 depicts the Preferred Reporting Items for Systematic Reviews and 
Meta-analysis (PRISMA) Search Strategy. A total of 427 articles from four databases 
were initially identified from the literature search. All references were imported into a 
reference management program and 80 duplicates were removed, leaving 347 articles 
remaining for review. Upon reviewing titles for relevance to this review, 194 articles 
were eliminated because they did not focus on older BCS and/or cognitive functioning. 
Abstract reviews were completed and 139 more records were removed due to not meeting 
inclusion criteria: (1) BCS under 60 years of age (n=107), (2) no cognitive measurement 
(n=12), (3) not English language (n=5), and (4) non-empirical articles (n=15). Fourteen 
full-text articles were reviewed. After reviewing the reference lists of those articles, 
another 4 full-text papers were identified. A total of 18 full-text articles were reviewed 
and 6 studies were eliminated due to: (1) lack of cognitive assessment measure and/or 
used a dementia diagnosis (n=5) [88-92] and (2) BCS had metastatic disease (n=1) [93]. 
 Articles included in this review were critically examined for their relevance to 
cognitive dysfunction in older BCS and for their scientific rigor. To date studies have 
been correlational, observational, and descriptive. Based on the rating system for the 
hierarchy of evidence for intervention/treatment criteria in Melnyk and Fineout-Overholt 
(2015), the levels of evidence for the research studies in this review varied ranging from 
level 4 (correlational, case-control or cohort studies) to level 6 (descriptive or qualitative 
studies) [94]. There have not been intervention trials, randomized control trials, or 
systematic reviews conducted in this area to date [94].  
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Study Characteristics 
A total of 12 articles met all eligibility criteria and were included in this review 
[23,24,34,39,41,43,95-100]. Publication dates ranged from January 2006 to December 
2019. Results from the data extraction are summarized in Table 2-1. The 12 studies in 
this review included 3,384 BCS and 1,197 healthy controls total. Notably, three teams of 
researchers (Hurria et al., Lange et al., and Mandelblatt et al.) conducted a total of 10 of 
the 12 studies. Each of the publications included in this review by these three teams of 
researchers were reviewed and found to present unique objectives and results were not 
duplicative in nature and thus, add to the body of knowledge in this area and were 
included in this review. Sample sizes varied significantly, from 28 BCS to 1280 BCS, 
among the studies reviewed. BCS ranged in age from 60 to 98 years in these studies. All 
12 of the studies included in this review are quantitative, observational studies 
[23,24,34,39,41,43,95-100], with 10 (83%) prospective [23,24,34,41,43,96-100], and two 
(17%) cross-sectional [39,95]. Of the 10 prospective studies, four studies [34,41,96,99] 
examined cognitive dysfunction with pre-treatment and post-treatment assessment, 6 
studies [23,24,43,97,98,100] were longitudinal examining cognitive dysfunction at 
multiple time points, including one study which examined cognitive dysfunction annually 
for up to 7-years post-treatment [23]. Of the two cross-sectional studies, one study [39] 
examined participants after surgery but before initiation of an adjuvant treatment and one 
study [95] focused on post-treatment survivorship, including BCS who were 10 years 
post treatment (M=16.8 years post-treatment) with standard chemotherapy.  
Measurement of cognitive dysfunction varied across studies. Two of the 12 
studies (17%) [41,95] employed only objective cognitive function measures. Three of the 
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12 studies (25%) [24,96,100] reported only subjective measures of cognitive dysfunction. 
The majority, seven of the 12 studies (58%) [23,34,39,43,97-99], reported both objective 
and subjective measures of cognitive function. In total, there were nine studies 
[23,34,39,41,43,95,97,99,98] that used objective measures of cognitive function and 10 
studies [96,34,43,24,39,97-100] that reported subjective measures of cognitive function. 
In the following section, results for objective cognitive dysfunction, including the 
prevalence, trajectory and associated factors will be presented, followed by similar results 
for subjective cognitive dysfunction in older BCS.  
Objective Cognitive Dysfunction 
Nine studies in this review included objective measures of cognitive function in 
older BCS [23,34,39,41,43,95,97,98,99]. Although the exact measures varied, most 
studies included assessments of the following cognitive domains including memory, 
executive functioning, processing speed, and language/verbal fluency.  
Prevalence 
 Table 2-1 presents the prevalence of objective cognitive dysfunction from each 
study and the definitions used to designate cognitive dysfunction. In the majority of the 
literature, significant objective cognitive dysfunction has been defined in the literature 
and in this review as 1.5 standard deviations (SDs) or 2.0 SDs below norm-based tests or 
healthy control groups on one or more objective neuropsychological test [101]. Prior to 
treatment, the prevalence of cognitive dysfunction ranged from 11% to 41% using 
objective neuropsychological assessments [39,41]. It was reported across studies that 
cognitive function post-treatment, measured by objective neuropsychological tests, up to 
49% in older BCS exhibited cognitive decline [34,41]. Cognitive domains identified as 
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impaired throughout the studies included memory, executive functioning, and speed of 
processing.  
Patterns emerged when objective cognitive dysfunction was examined over time. 
Lange and colleagues (2019) [99] identified five patterns of cognitive decline from pre- 
to post-treatment among 118 older, early stage BCS, 65 years of age and older. All older 
BCS experienced cognitive decline at differing rates, some declined at a rate similar to 
normal ageing, while others declined at an accelerated rate with pathological decline, and 
none improved form pre- to immediately post-treatment.  
Associated Factors  
Table 2-2 identifies all of the factors that were examined in review of these 
articles and denotes those which were significantly related to objective cognitive 
function. Based on the findings, factors associated with objective cognitive dysfunction 
were grouped into demographic, medical, and treatment factors, cancer-related 
symptoms, physical/functional factors, and quality of life (QoL), a thorough summary is 
provided below.   
Demographic. Of the nine studies that used objective measures, three [34,39,98] 
examined the relationship between age and objective cognitive dysfunction with two 
[34,98] identifying that older age was related to cognitive dysfunction. In Lange et al. 
(2016) [34], being 70 years of age and older was related to objective cognitive 
dysfunction, specifically executive functioning. Mandelblatt et al. (2018) [98] found that 
older age was significantly associated with lower cognitive functioning scores at baseline 
among 344 older BCS in the study. Only two studies [34,39] that used objective measures 
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investigated the relationship between education and objective cognitive dysfunction, 
neither found significant results. 
Medical and Treatment. Four studies [34,39,41,98] assessed comorbidities in 
relationship to objective cognitive dysfunction, one study [98] found significant 
associations between comorbidity and cognitive dysfunction. Results from the 
Mandelblatt et al. (2018) study indicate that individuals with more than two comorbid 
conditions or a diagnosis of diabetes had significantly lower cognitive scores at baseline 
[98]. Five studies [23,34,39,41,98] assessed type of treatment or therapy in relationship to 
objective cognitive dysfunction, with two studies [34,98] finding significant 
relationships. One of those studies by Lange et al. (2016) [34] found that those who 
received chemotherapy had more objective cognitive dysfunction than those that did not 
receive chemotherapy but received radiation therapy. Mandelblatt et al. (2018) found 
similar results in that those who received chemotherapy experienced declines in their 
cognitive scores over time, specifically in attention, processing speed, and executive 
function cognitive domains whereas those who did not receive chemotherapy but did 
receive hormonal therapy improved over time [98].  
Two studies [34,39] examined number and type of medications taken. 
Medications examined were those considered level 3 on the World Health Organization 
analgesic ladder, anxiolytics, antidepressant treatments, and hypnotics and their 
association with objective cognitive dysfunction. Results were mixed with one study by 
Lange and colleagues (2016) [34] found that these level 3 medications were significantly 
associated with poorer visual episodic memory on neuropsychological exam, while this 
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relationship was not identified in other cognitive domains nor in an earlier study by this 
team [39].  
Cancer-Related Symptoms. The relationship between objective cognitive 
dysfunction and anxiety was examined in three of the nine studies [34,39,98], although 
none found significant associations. Depression or depressive symptoms were assessed in 
relationship to objective cognitive dysfunction in five studies [34,39,41,95,98], with no 
significant relationships identified. Fatigue related to objective cognitive dysfunction was 
examined in three studies [34,39,98], with no significant relationships identified. In one 
study sleep disturbance was examined in relationship with objective cognitive 
dysfunction and was significant [97]. Tometich and colleagues (2019) examined 
objective cognitive dysfunction and the association with cancer-related symptoms 
(anxiety, depression, fatigue, sleep disturbance, and pain) in 319 older (60 years of age 
and older) BCS. However, in this study these psychoneurological symptoms were 
clustered into two groups, high-symptom and low-symptom groups, for analysis [43]. 
The group with high- psychoneurological, cancer-related symptoms experienced worse 
objective cognitive dysfunction [43].   
Physical/Functional. In three studies [34,39,41] researchers assessed physical 
function/performance status and two studies [39,98] assessed frailty in relationship with 
objective cognitive dysfunction. Mandelblatt and colleagues [98] found frailty, measured 
by an adapted Searle’s deficits accumulation index resulting in scores categorized into 
robust, pre-frail, and frail, to be related to objective cognitive dysfunction; the other study 
did not find this significant relationship [102]. In three studies [34,39,41] researchers 
assessed activities of daily living, basic self-care skills that are required to maintain 
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independent living, and none found significant results related to objective cognitive 
dysfunction in older BCS. 
Quality of Life. QoL, measured by scales specific to cancer diagnosis and 
treatment, was assessed in two studies [34,41], both studies found significant yet mixed 
results. Hurria, Rosen, and colleagues [41] found that BCS whose objective cognitive 
dysfunction worsened from pre-treatment to post-treatment was related to significantly 
higher QoL scores. The authors hypothesized that although objective cognitive 
dysfunction worsened from baseline to 6-months after chemotherapy, QoL may have 
been worse at baseline due to just receiving a cancer diagnosis and likely improved at 6-
months after chemotherapy due to finishing treatment [13]. Lange et al. (2016) found an 
objective decline in at least one cognitive domain was related to the QoL subscale 
(FACT-Cog) [34]. 
Subjective Cognitive Dysfunction 
Ten of the 12 studies in this review employed a measure of subjective cognitive 
function [23,24,34,39,43,96-100]. Subjective cognitive functioning was measured in a 
variety of ways with instruments ranging from two questions from a larger QoL 
questionnaire (i.e. European Organization for Research and Treatment of Cancer Quality 
of Life Questionnaire Core 30 (EORTC QOL-C30)) to a scale focused solely on 
cognitive functioning in cancer patients with 41 questions and four separate sub-scales 
(i.e. Functional Assessment of Cancer Therapy - Cognitive Function test (FACT-Cog)). 
Prevalence 
Table 2-1 presents prevalence of subjective cognitive dysfunction from each study 
included. Higher prevalence of cognitive dysfunction was noted when subjective 
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measures were used, with up to 64% reporting cognitive dysfunction prior to adjuvant 
treatment. Importantly, it was also noted that those older BCS who had poorer cognitive 
functioning at baseline also had greater cognitive decline after adjuvant treatment, with 
up to 51% of older BCS reporting a significant decline in their memory post treatment. 
Freedman et al. (2013) found that subjective cognitive dysfunction increased after 
treatment, from 6% pre- to 12% post-treatment and at 2-years post-treatment 9% of older 
BCS reported cognitive dysfunction.  
When subjective cognitive dysfunction was examined over time, a few patterns 
emerged. Mandelblatt and colleagues (2016) [23] identified three patterns of subjective 
cognitive dysfunction from before to after treatment in 1280 older BCS 65 years of age 
and older. Older BCS experienced subjective cognitive decline ranging from ‘very slight’ 
to ‘steep’ or ‘accelerated’ decline from pre- to post-treatment; none improved [23].  
Associated Factors 
Demographic. Of the nine studies that used subjective cognitive dysfunction 
measures, five studies [23,24,34,39,98] examined the relationship between age and 
subjective cognitive dysfunction with one [98] identifying that older chronologic age was 
associated with lower baseline subjective cognitive function. Only one of the studies [24] 
which employed subjective measures looked at the relationship of education and 
subjective cognitive dysfunction and found that lower education level was associated 
with poorer subjective cognitive dysfunction.  
Medical and Treatment. Two studies [23,24] assessed comorbidities in 
relationship to subjective cognitive dysfunction and both found significant associations 
between increased number of comorbidities and greater subjective cognitive dysfunction. 
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Specifically, Mandelblatt and colleagues (2016) found that cardiovascular disease was 
significantly correlated with accelerated cognitive dysfunction, although this finding did 
not hold in multivariate analyses [23]. Freedman et al. (2013) found more comorbid 
conditions to be significantly related to cognitive dysfunction at baseline before treatment 
[24]. All studies collected information on BCS treatment modalities, five studies 
[23,24,34,41,98] assessed type of treatment in relationship to subjective cognitive 
dysfunction and two studies [23,34] found that those who received chemotherapy had 
more subjective cognitive dysfunction than those that did not receive chemotherapy. 
Medications and their potential association with subjective cognitive dysfunction were 
not addressed in any of the studies.  
Cancer-Related Symptoms. Three of the nine studies [23,24,39] examined 
anxiety, all found anxiety to be significantly related to poorer subjective cognitive 
dysfunction. Three studies [23,24,39] assessed depression or depressive symptoms in 
relationship to subjective cognitive dysfunction and two of those studies [23,39] found 
significant relationships with those with more depressive symptoms reporting more 
cognitive dysfunction. Two studies [24,39] examined fatigue and found that fatigue was 
significantly related to subjective cognitive dysfunction, where those with more fatigue 
also reported more cognitive dysfunction. One study [97] assessed sleep disturbance and 
found a significant relationship between sleep disturbance and subjective cognitive 
dysfunction. Tometich et al. (2019) examined the association between subjective 
cognitive dysfunction and a psychoneurological symptom cluster (i.e. anxiety, 
depression, fatigue, sleep disturbance, and pain), the symptom clusters were separated 
into two groups high-symptom and low-symptom groups for analysis [43]. The group 
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with high-psychoneurological, cancer-related symptoms experienced worse subjective 
cognitive dysfunction [43].   
Physical/Functional. One study [23] assessed physical function/performance 
status and two studies [23,98] assessed frailty in relationship to subjective cognitive 
dysfunction. Mandelblatt and colleagues (2016) found both worse physical functioning 
and increased frailty to be related to increased subjective cognitive dysfunction overtime 
[23]. Mandelblatt et al. (2018) also found frailty to be significantly related to subjective 
cognitive dysfunction [98]. None of the studies in this review assessed activities of daily 
living in relationship to subjective cognitive dysfunction.  
Quality of Life. QoL was assessed by one study [39], Lange and colleagues 
(2014) found QOL scores, a FACT-Cog subscale, to be significantly related to subjective 
cognitive dysfunction on other FACT-Cog subscales, with poorer perceived cognitive 
dysfunction related to poorer QOL [39]. Mandelblatt et al. (2019) [100] addressed 
subjective cognitive dysfunction and the impact upon well-being and found that cognitive 
dysfunction among older BCS did impact physical, functional, and emotional well-being.  
Discussion 
This integrative review identified and synthesized the current evidence regarding 
cognitive dysfunction in older BCS including the prevalence and factors associated with 
objective and subjective cognitive dysfunction. A substantial percentage of BCS were 
noted to incur objectively measured cognitive dysfunction when compared to healthy, 
non-cancer controls or published norms. In addition, prevalence rates in these older aged 
BCS studies were slightly higher than objective cognitive dysfunction prevalence rates 
published in the all age BCS population [85]. 
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The prevalence of subjective cognitive dysfunction was noted to be higher than 
objectively measured cognitive dysfunction which is consistent with the larger all age 
BCS literature [13]. In addition, similar subjective cognitive dysfunction prevalence rates 
have been noted in all age BCS research [103,104]. Higher prevalence of subjective 
cognitive dysfunction could be related to the idea that objective neuropsychological 
assessments may not measure the more subtle cognitive dysfunction incurred by BCS, 
that subjective assessments of cognitive dysfunction are actually tapping into other 
factors such as psychological distress, and/or that objective and subjective cognitive 
dysfunction are independent phenomena in cancer patients [105]. However, both 
subjective and objective cognitive dysfunction are important and should be considered by 
health care providers. In fact, recognition and validation of subjective cognitive 
dysfunction alone has been deemed important for many BCS [87]. National 
Comprehensive Cancer Network guidelines recommend first using self-report to discern 
if a patient is experiencing cognitive dysfunction [33]. For older BCS this assessment 
should take place during the initial geriatric assessment and continue at regular intervals 
over the cancer care trajectory including survivorship [83,84].  
Multiple studies examined cognitive dysfunction pre- to post-treatment or in 
trajectories with most studies identifying increased prevalence of cognitive dysfunction 
post-treatment. The majority of older BCS had lower pre-treatment cognitive functioning 
compared to non-cancer controls and then exhibited varying levels of decline from 
‘slight’ to ‘accelerated’ cognitive decline post-treatment. Thus, overall the majority of 
BCS experience poorer performance in cognitive functioning than their non-cancer 
control counterparts. These trajectories highlight the need and importance of assessment 
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and re-assessment to identify any changes in older BCS cognitive functioning over the 
course of the cancer care trajectory. In addition, older cancer patients have reported 
healthcare provider’s assessment of and maintenance of cognitive ability over the cancer 
trajectory as highly valued [84]. 
The studies in this review examined various factors that could potentially be 
associated with cognitive dysfunction. Empirical studies examined the association of 
cognitive dysfunction with demographic, medical, and treatment factors, cancer-related 
symptoms, physical functioning/performance factors, and quality of life.  Although 
results were mixed, objective and subjective cognitive dysfunction was associated with 
age, comorbidities, chemotherapy receipt, sleep, psychoneurological symptom cluster, 
frailty, and QoL.  
Older age was a significant factor associated with cognitive dysfunction in 
multiple studies examined, which alone is not novel [34,98]. However, it is important to 
note that only studies with BCS who were 60 years of age and older were included. This 
finding suggests the relative significance of age as a factor in cognitive dysfunction in 
BCS. This is also of particular interest due to the increased life expectancy of the general 
population, with the fastest growing subpopulation identified as those age 85 years of age 
and older. This rapidly growing subset of BCS may be at most risk of cognitive 
dysfunction among older BCS and may need tailored evidence-based interventions aimed 
at promoting independence and everyday cognitive functioning [106,107].  
The overall health of the BCS was also noted to be associated with cognitive 
dysfunction. This review found that BCS with a higher number of comorbidities had 
poorer cognitive functioning [23,24,98]. Specifically, some researchers noted that 
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cardiovascular disease and diabetes in particular were related to cognitive dysfunction. 
These findings are similar to the larger literature in which cardiovascular disease and 
diabetes, individually have been linked to cognitive dysfunction [108,109]. Together, this 
may indicate that those older BCS with either an increased number of comorbidities 
and/or comorbidities that include cardiovascular disease and diabetes may have an even 
greater risk for cognitive dysfunction. 
Older BCS who take more, or specific types of medications, may also have 
concerns regarding their cognitive functioning. Although only a couple of studies have 
examined the link between medication use and objective cognitive dysfunction, 
researchers noted specifically that medications considered level 3 on the World Health 
Organization analgesic ladder were related to poorer objective cognitive functioning [34]. 
This is an important finding to consider as older BCS are at risk for polypharmacy [83]. 
Assessment and management of medication prescription and adherence as it relates to 
cognitive dysfunction has largely been ignored in the broader BCS literature and is an 
important area for further examination in this older BCS sub-population.  
Chemotherapy has been studied in the larger all age BCS literature and multiple 
studies have identified chemotherapy as contributing to cognitive dysfunction, although 
results have been mixed [110,111]. Chemotherapy has been shown to have direct 
neurotoxic effects. A review by McDonald and Saykin (2013) of imaging studies in BCS 
found that those BCS who had undergone chemotherapy treatment consistently showed 
white and gray matter changes in the brain that were also related to both objective and 
subjective cognitive dysfunction [112]. As in the larger all age BCS literature, 
chemotherapy has been examined in relationship to both objective and subjective 
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cognitive dysfunction in older BCS as well. Researchers have also found chemotherapy 
receipt to be significantly related to both objective and subjective cognitive dysfunction 
among older BCS, although results were also mixed. As the population continues to age, 
more BCS will be exposed to neurotoxic chemotherapy treatments and potentially 
experience cognitive dysfunction. Assessing the type of treatment, especially 
chemotherapy, is an important factor to consider due when assessing for cognitive 
dysfunction in older BCS. 
Cancer-related symptoms may also impact cognitive dysfunction. Similar to all 
age BCS, cancer-related symptoms of anxiety, depression, fatigue and sleep disturbance 
have been noted to be strongly associated with subjective cognitive dysfunction 
[103,113]. However, these individual symptoms were not found to be related to objective 
cognitive dysfunction except for sleep. One study did find that a psychoneurological 
symptom cluster of anxiety, depression, fatigue, sleep disturbance, and pain was related 
to both objective and subjective cognitive dysfunction [43]. However, the manuscript 
does not indicate type of pain or use of pain medication that may have contributed. 
Overall, though cancer-related symptoms should be assessed in relationship to cognitive 
dysfunction. There are treatments for some of these other symptoms and resolution of 
these symptoms may address and alleviate concerns related to cognitive dysfunction. 
Sleep disturbance was one of the main symptoms noted in findings for both 
objective and subjective cognitive dysfunction in older BCS. Similar results have been 
noted in all age BCS with sleep disturbance negatively associated with cognitive 
dysfunction [35,37,38,114]. This finding is important as older adults are already at a 
greater risk for sleep disturbances making this an important area for assessment and 
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surveillance in cancer care with the implications on cognitive functioning [115,116]. 
Studies of older adults report that short or long sleep duration and/or having sleep 
complaints or disturbances such as difficulty falling or staying asleep have an increased 
risk of cognitive dysfunction [117]. In addition, sleep disturbance may be amenable to 
treatment, if sleep is improved, cognitive dysfunction in this older BCS population could 
be minimized.  
Although results were mixed, decreased physical functioning and increased frailty 
were significantly related to cognitive dysfunction. These relationships may have 
significant implications for older BCS. Research in the general aging population has 
identified that physical limitations, frailty, and cognitive dysfunction combined can have 
serious ramification for older adult’s ability to live independently making these 
relationships increasingly important in older BCS [107,118]. In addition, these negative 
implications to independence can require significant time and economic cost to families 
as well as society [118]. 
QoL or well-being was significantly related to both subjective and objective 
cognitive dysfunction. This finding highlights the importance of addressing cognitive 
dysfunction and its ramifications in older BCS which, has been understudied. QoL is an 
important area of focus for older adult cancer patients as researchers have shown that 
decreased QoL in older cancer patients impacts function, disability, treatment 
continuation, and survival [119]. These consequences underscore the importance of the 




Strengths and Limitations 
In this review, the literature regarding cognitive dysfunction in older BCS was 
synthesized, who make up the majority of the total BCS population. This review 
identifies factors that are associated with cognitive dysfunction and lays the groundwork 
for evidence-based interventions for older BCS that both focus on reducing factors that 
impede brain capacity and promote cognitive reserve [120]. There are limitations of this 
review that are also worth noting. Multiple studies had small samples and two studies had 
samples under 30 BCS. Although, each study included in this review reported different 
outcomes or timeframes, it was clear that three main research teams conducted the trials 
and therefore, may have utilized the same samples (e.g. published baseline in one 
manuscript and trajectory overtime in another manuscript). This may have limited the 
scope and generalizability of the findings, yet each contributed independently to what is 
known regarding cognitive dysfunction in older BCS. In addition, research teams varied 
in their use of cognitive measures making it difficult to compare cognitive dysfunction in 
older BCS across multiple studies.  
Implications for Future Research 
 This review identified important research needs. More reach is needed that 
examines cognitive dysfunction among older BCS across the cancer care trajectory. Most 
of the studies were limited and failed to examine cognitive dysfunction beyond a few 
years post-treatment in older BCS. Future research needs to address the long-term 
concerns of cognitive dysfunction of older BCS. In addition, evaluation of cognitive 
dysfunction varied between studies making comparisons difficult. Researchers need to 
use the international recommendations identified by the International Cancer and 
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Cognitive Task Force [54]. This review also identified some correlated symptoms that are 
common in all age BCS as well as some unique factors associated with cognitive 
dysfunction in older BCS. Older BCS may have a higher number of comorbidities, 
especially diabetes and cardiovascular issues, which may confound the issues associated 
with cognitive dysfunction. Issues of polypharmacy, sleep disturbance, and 
psychoneurological symptom clusters should be examined for contributing to cognitive 
dysfunction in older BCS. In addition, ramifications of cognitive dysfunction including 
physical limitations, frailty, and decrements in quality of life may be important endpoints 
for future research. Interventions are needed to mitigate, prevent, and/or slow cognitive 
dysfunction in older BCS. Interventional research for cognitive dysfunction should be 
tailored to the specific needs of older individuals and may need to target multiple factors 
to support cognitive capacity.  
Implications for Oncology Nursing Practice 
For oncology nursing practice, the findings of this review help to highlight the 
prevalence of cognitive dysfunction in older BCS as well as describing some factors that 
could be related to cognitive dysfunction that are important to consider in clinical 
practice. Assessment, surveillance, and management of comorbid conditions in older 
BCS is of particular importance for nursing. A thorough geriatric assessment should be a 
key component of the cancer care continuum for older BCS [83,84,120]. Cognitive 
dysfunction before, during, and after breast cancer diagnosis and treatment should be a 





To my knowledge, this is the first integrative review to examine the prevalence of 
cognitive dysfunction and factors associated with cognitive dysfunction in the older BCS 
population. By collecting and synthesizing the current evidence and presenting the gaps 
in knowledge, this review is relevant to both clinical practice and research. Findings from 
this review indicate both objective and subjective cognitive dysfunction are a significant 
concern that warrants attention in older BCS, although the literature to date is limited. 
Cognitive dysfunction can be associated with numerous factors as evidenced by the 
findings of this review. Of particular interest in the older BCS population specifically, 
would be older age, increased number of comorbidities, as well as specific comorbidities 
such as diabetes and cardiovascular issues, chemotherapy receipt, sleep, 
psychoneurological symptom cluster, frailty, and QoL as older adults tend to experience 
more of these issues than younger adults [107]. Many factors related to cognitive 
dysfunction identified by this review may be magnified in the older BCS and should be 
incorporated in a thorough comprehensive geriatric assessment at each cancer 




Figure 2-1 Preferred Reporting Items for Systematic Reviews and Meta-analysis 

































Records remaining after 
duplicates are removed
(n=347)
Records with irrelevant 
titles removed (n=194)
Records with abstracts 
screened for eligibility
(n=153)
Records excluded after 
abstract screen (n=139)
•Not 60+ years old: 107
•No cognitive measure: 12
•Not English: 5
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No objective cognitive measure used 
 
Subjective: 
• 64% reported poor memory prior to CT 
• 51% reported a decline in memory at 6 
months post CT 






No significant associated 























• 11% scored 2 SDs below the norm on 2 
or more tests prior to CT at baseline 
• 29% scored 2 SDs below the norm on 2 
or more tests at 6 moths post CT 
• Domains most affected were visual 
memory, spatial function, psychomotor 
function, and attention 
• BCS were classified as having CD if they 
scored ≥ 2 SDs below published norms 
on ≥ 2 tests 
 
Subjective: 
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No objective prevalence was reported 
• BCS scored significantly lower in 
executive functioning, working memory, 
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Prevalence  Associated Factors 
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treatment 
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compared to NCC 
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of treatment, 12 
months post, 18 
months post, 
and 24 months 
post treatment 
Objective: 
No objective cognitive measure used 
 
Subjective: 
• 6% reported CD prior to treatment at 
baseline 
• 6% reported CD mid-treatment 
• 10% reported CD at the end of treatment 
• 12% reported CD at 12 months post 
treatment 
• 7% reported CD 18 months post 
treatment  





Subjective: (at baseline) 
• Education 
• Positive nodes 
• Comorbidities 
• Anxiety 























• 41% had CD prior to treatment  
• 29% exhibited CD on 1 test 
• 12% exhibited CD on 2 or more tests 
• CD was defined as a z-score of ≤ 1.5 SDs 
on 2 or more tests, or a z-score of ≤ 2.0 




• Subjective CD (only with 
verbal episodic memory)  
 
Subjective: 




















Prevalence  Associated Factors 
• NCC had more complaints on Perceived 
CD and Cognitive Abilities FACT-Cog 
subscales than BCS 
• BCS had more complaints than NCC on 
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Assessments 
took place after 
surgery 




and after the 
end of the first 




• 41% had CD prior to treatment at 
baseline 
• 49% experienced cognitive decline 
between T1 and T2 in at least 1 domain  
• CD was defined as 1.645 SDs below 
NCC in at least 1 domain based upon 
reliable change index 
 
Subjective: 
• BCS with more subjective CD at T1 were 
those who reported greater subjective CD 
at T2 (not clinically significant) 
Objective: 
• Subjective cognitive 
complaints 
• Age (executive function) 
• CT treatment (executive 
function) 
• Medications (visual episodic 
memory) 




• Subjective cognitive 
complaints were predictive 
of objective cognitive 
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for up to 7 
years 
3 trajectory groups noted  
• 42% were in the ‘maintained high’ group 
(good cognitive function baseline – 
decline = normal aging) 
• 50% were in the ‘phase shift’ group 
(lower cognitive function at baseline – 
decline = normal aging) 
• 8% were in the ‘accelerated decline’ 
(lower cognitive functioning baseline – 
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No objective prevalence was reported 
 
Subjective: 
No subjective prevalence was reported 
Objective: 
• Sleep disturbance 
• APOE ε4 carrier status 
 
Subjective: 
• Sleep disturbance 
















Prevalence  Associated Factors 
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surgery 
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5 trajectory groups noted  
• 15% had ‘normal aging’ (cognitive 
function = NCC at baseline – decline = 
normal aging/NCC) 
• 12% had ‘nonpathological decline’ 
(cognitive function = NCC at baseline – 
decline slightly > NCC/normal aging but 
not to the level of CD) 
• 31% had ‘pathological decline’ 
(cognitive function = NCC at baseline – 
decline > NCC/normal aging resulting in 
CD) 
• 36% had ‘phase shift hypothesis’ (CD at 
baseline – decline = NCC/normal aging) 
• 6% had ‘accelerated aging hypothesis’ 
(lower cognitive functioning baseline – 
steep decline > NCC/normal aging)   
 
Subjective: 
No subjective prevalence was reported 
Objective: 
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months, and 36 
months post-
treatment  
Older BCS reported significantly more 
cognitive problems than NCC 
 
Self-reported cognitive 
problems had a significant 






















months, and 24 
months  
Objective: 
No objective prevalence was reported 
 
Subjective: 
No subjective prevalence was reported 
Objective: 
• High psychoneurological 
symptoms (anxiety, 




• High psychoneurological 
symptoms (anxiety, 
depression, fatigue, sleep 
disturbance, pain) 
 
BCS = breast cancer survivor; BC = breast cancer; CD= cognitive dysfunction; CT = chemotherapy; QoL = quality of life; ADL = activities of daily 
























































































































Objective Cognitive Measures 
Hurria, Rosen 
(2006) 
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Up until recently older individuals were excluded from many cancer studies and 
are still underrepresented in cancer research as a whole [121]. With the rapidly growing 
number of older adults, there is an increased need for research in this population [16]. In 
addition, with improved prevention, screening, and treatment for cancer, more older 
adults are receiving treatment and older survivors are living longer after treatment 
[17,106]. Older BCS face many unique care needs during their diagnosis and treatment 
for breast cancer, some of which may linger into survivorship and may be compounded 
with normal aging [122]. One issue older BCS may face is cognitive dysfunction 
[98,122]. 
Cognitive dysfunction is a common concern among all age BCS. Older BCS may 
be at an increased risk due to a number of factors, including normal aging processes, 
lower cognitive reserve, and the neurotoxic effects of cancer treatment [3]. Cognitive 
dysfunction has been defined as a complex symptom identified by cognitive changes that 
negatively impact higher-order mental processes including immediate memory, delayed 
memory, attention, executive function-working memory, and verbal fluency, which are 
commonly impaired cognitive domains in all aged BCS. Cognitive dysfunction is 
measured in BCS by both standardized objective (neuropsychological) assessments and 
subjective (self-report) assessments. The association between objective and subjective 
cognitive dysfunction measures has been examined in all age BCS with most studies 
indicating that they are unrelated [113,123]. However, this relationship has not been fully 
examined in older BCS. Both objective and subjective measures are important and have 
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their uses. Self-report is often used in the clinical setting and is often the first indication 
from the BCS that there is a significant problem for the healthcare provider to address 
[33,42]. Depending upon the severity of the problem or level of concern, a 
neuropsychological assessment may be warranted [42]. Thus, understanding the 
relationship between objective and subjective cognitive assessments may assist in fully 
characterizing cognitive dysfunction in the older BCS.  
Examining factors that may be associated with both objective and subjective 
cognitive dysfunction is crucial. This information may be critical to identifying factors 
that are common, overlapping, or compounding. Ultimately, this information may signal 
a potential risk for cognitive dysfunction and/or may lead to identifying factors that 
would be amenable to intervention in the older BCS. Identifying factors related to 
cognitive dysfunction will also be useful for intervention development in older BCS 
specifically.  
Based upon a modified Hess and Insel conceptual framework (which identifies 
potential antecedents associated with cognitive dysfunction in cancer survivors) [50] and 
the larger BCS literature, there are factors that may be significantly related to cognitive 
dysfunction and help to identify and characterize cognitive dysfunction in older BSC 
[50]. Demographic (age and education), medical (comorbidities), and treatment factors 
(time since diagnosis and breast cancer stage), have been shown to be significantly 
related to cognitive dysfunction [23,24,34,98]. In addition, other cancer-related 
symptoms, including depressive symptoms, anxiety, fatigue, and sleep disturbance have 
been previously linked with cognitive dysfunction [23,24,39,97]. However, in the all age 
BCS and the smaller volume of literature focusing on older BCS, these findings have 
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been mixed. In addition, studies in the older BCS have only followed BCS for up to 2-3 
years post-diagnosis, and; thus, have failed to elucidate significant factors associated with 
cognitive dysfunction in older BCS who further into survivorship and may be 
experiencing longer term symptoms or late effects of treatment [122].   
With the gaps in knowledge, mixed results, and the limited research in the older 
(60 years of age and older) BCS population and even further limited research in the time 
span of 3-8 years post diagnosis in older BCS, more research is needed to better 
understand this complex symptom in older BCS. Therefore, the purpose of this study is to 
examine the relationships between objective and subjective cognitive dysfunction and 
factors potentially associated with both subjective and objective cognitive dysfunction in 
older BCS. Specific aims are to examine the relationships between: 2a) objective 
cognitive function and subjective cognitive function in older BCS, and 2b) demographic 
(age and education), medical (comorbidities), and treatment factors (time since diagnosis 
and breast cancer stage), and cancer-related symptoms (depressive symptoms, anxiety, 
fatigue, and sleep disturbance) and objective cognitive function (immediate memory, 
delayed memory, attention, executive function-working memory, and verbal fluency) and 
subjective cognitive function (subjective attention) in older BCS. 
Methods 
A descriptive, secondary data analysis study design was used. Cross-sectional 
data for this dissertation study were leveraged from a large, United States wide BCS 
study titled “Quality of Life in younger Breast Cancer Survivors” (American Cancer 
Society RSGPB-04-089-01, PI: V. Champion). The overall aim of the original study was 
to better understand quality of life in younger versus older BCS [52].  
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Population and Data Collection 
Participants were eligible for this dissertation study if they were: 1) female BCS, 
2) 60 years of age and older at the time of breast cancer diagnosis, 3) 3-8 years post-
diagnosis at the time of survey completion/data collection without a recurrence or other 
cancers (exception skin cancer), 4) stage I-IIIa at initial breast cancer diagnosis, 5) able to 
read and write English, 6) treated with a chemotherapy as part of their initial treatment 
regimen (Adriamycin, Paclitaxel, and Cyclophosphamide), and 7) completed the 
neuropsychological assessment.  
Participants were recruited from Indiana University (IU) and 97 Eastern 
Cooperative Oncology Group (ECOG) sites across the United States. Human subjects 
protection was obtained for the study from IRBs at each cooperating site. Potential 
participants were identified by the statistical center of the ECOG who in turn notified the 
BCS’s treating physician, who obtained permission to forward their name and contact 
information to study staff. BCS were mailed information explaining the study and then 
were contacted via telephone. Interested BCS were then mailed an informed consent and 
questionnaire with postage-paid return envelopes and a date was set for the telephone 
neuropsychological assessment. Trained research assistants then de-identified and entered 
the data in a password protected database. Neuropsychological assessments were 
performed by trained staff via the telephone under the direction of a licensed 
psychologist, expert in neuropsychological assessments, and study coinvestigator. 
Participants received $25 for completing and sending back the survey and $25 for 





Demographic, Medical, and Treatment Factors. Demographic, medical, and 
treatment data were collected via investigator-initiated questionnaire (self-report) and 
medical record. This information includes age at initial breast cancer diagnosis and 
current age at data collection, race/ethnicity, education, income, marital status, number of 
comorbidities, self-reported specific comorbid conditions, breast cancer diagnosis date 
and stage, and cancer treatment (surgery, radiation). 
Cancer-Related Symptoms. Cancer-related symptoms included instruments 
measuring depressive symptoms, anxiety, fatigue, and sleep disturbance. Depressive 
symptoms were measured using the Center for Epidemiologic Studies Depression Scale 
(CES-D). The CES-D is a 20-item instrument, that assesses the presence and severity of 
depressive symptoms over the past week, potential scores range from 0-60, with higher 
scores indicating more depressive symptoms [55,56]. In this study, the CES-D had a 
Cronbach alpha of .84. Anxiety was measured using the Spielberger State-Trait Anxiety 
Inventory (STAI)-State sub-scale, a 20-item scale assessing state anxiety at this moment, 
potential scores range from 20-80, with higher scores indicating more anxiety [58]. In 
this study, the STAI-State sub-scale had a Cronbach alpha of .93. Fatigue was measured 
using the Functional Assessment of Cancer Therapy-Fatigue (FACT-F), a 13-item 
measure, that assesses symptoms of fatigue over the last four weeks, potential scores 
range from 0-52, with higher scores indicating less fatigue [59]. In this study, the FACT-
F had a Cronbach alpha of .93. Sleep was measured using the Pittsburgh Sleep Quality 
Index (PSQI) - sleep disturbance sub-scale, a 9-item sub-scale, used to assess sleep 
disturbances during the past four weeks, with potential scores ranging from 0-3, with 
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higher scores indicating more sleep disturbance or worse sleep [60]. In this study, the 
PSQI-sleep disturbance subscale had a Cronbach alpha of .65. 
Objective Cognitive Function. Objective cognitive function, including 
immediate memory, delayed memory, attention, executive function-working memory, 
and verbal fluency were measured using a neuropsychological battery. All of the 
neuropsychological assessments used in this study are reliable, valid, have been used in 
BCS, and were performed via telephone by trained staff. Immediate and delayed memory 
was assessed using the Rey Auditory-Verbal Learning Test (AVLT). The AVLT is a 15-
item, five trial word list learning task [63,65,66]. For the AVLT, the tester says the 15 
words in the list and the participant tries to remember the words. Immediate memory is 
the sum of the five learning trials and delayed memory is a free recall of the list 
approximately 30 minutes later, higher scores on both indicate better functioning. 
Attention and executive function-working memory were assessed using the Wechsler 
Adult Intelligence Scale IV (WAIS) - Digit Span Forward and Backward (respectively), a 
reliable assessment used previously in BCS [67,68]. The subscales of the Digit Span 
Forward (attention) and Backward (executive function-working memory) will be reported 
separately as two difference cognitive domains in this study. Digit Span-Forward 
specifically assesses attention. For the Digit Span-Forward test, the tester says a string of 
digits and the participant must recite the digit string in the same order it is given. Digit 
Span-Backward specifically assesses executive function-working memory. For the Digit 
Span-Backward test, the tester says a string of digits and the participant must recite the 
digit string in the reverse order it is given. Digit Span uses verbal repetition of digit 
strings forward and backward that gradually get longer. The score for Forward and 
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Backward separately is the number of digit strings correctly recited, higher scores 
indicate better functioning. Verbal fluency was measured using the Controlled Oral Word 
Association Test (COWA), a reliable measure consistently used in the BCS population 
[69,70,124]. For the COWA test, the tester gives a letter of the alphabet and the 
participants tries to produce as many words they can think of that begin with the given 
letter in 1-minute, higher scores indicate better functioning.  
Subjective Cognitive Function. Subjective cognitive function was measured 
using the Attentional Function Index (AFI). The AFI is a 13-item scale used to assess 
perceived effectiveness in common activities requiring attention, working memory, and 
executive function at the present time [71]. Potential scores on the AFI range from 0-130, 
with higher scores indicating better attention or subjective cognitive functioning [71]. In 
this study, the AFI had a Cronbach alpha of .80. There are predetermined cut points for 
the AFI used in the literature to indicate level of attention functioning; <50 indicates 
low/poor attention function, 50-70 indicated moderate attention function, and >75 
indicated good attention function [71].  
Statistical Analysis 
Descriptive statistics were computed for sociodemographic, medical, and 
treatment variables to describe the sample. Descriptive statistics were also computed to 
ensure data quality, identify out of range values, and evaluate the assumptions of 
statistical tests including normality and intercorrelation of independent variables. Level 




Prevalence of cognitive dysfunction on each neuropsychological assessment was 
determined by creating then comparing z-scores for each assessment for older BCS and a 
comparison group of non-cancer controls (NCC). Data for the NCC was provided by the 
Indiana Alzheimer Disease Center Clinical Core Study, a database that includes data 
from healthy older adult participants with no known neurological disease. NCC data from 
the Indiana Alzheimer Disease Center was used for comparison because the studies used 
the same neuropsychological battery, presented in the same order and format, thus, 
exposing participants to a comparable level of fatigue when testing. In addition, NCC 
subjects were sex- (female) and age-match (within +/- 5 years) to the BCS sample, 
providing a better comparison group than published normative data [125]. Based on the 
literature, 3 cut-point scores of cognitive dysfunction were derived including 1.0 SD 
(<16th percentile) below the mean or ‘mild dysfunction’, 1.5 SD (< 7th percentile) below 
the mean or ‘mild-moderate dysfunction’, and 2.0 SDs (<2nd percentile) below the mean 
or ‘moderate dysfunction [126]. We created groups for BCS at each cut point to 
document prevalence of cognitive dysfunction [126]. In clinical practice, it is commonly 
accepted to use the 16th percentile or 1.0 SD below the mean, as cutoff score for 
‘abnormality’ [126]. Count and percent of BCS within each group were calculated for 
each test. The AFI has cut points for attention functioning published. We used these cut 
points in order to provide count and percent of BCS within each level of function, from 
low/poor attention function to good attention function [71]. 
The accomplish aim 2a, Pearson bivariate correlations were used to examine the 
relationship between objective and subjective cognitive functioning. To accomplish aim 
2b, separate multiple linear regression models were used to examine the relationship 
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between the independent variables (demographic factors [age at neuropsychological 
assessment and number of years of education], medical factors [number of 
comorbidities], treatment factors [time since diagnosis and breast cancer stage], and 
cancer-related symptoms [depressive symptoms, anxiety, fatigue, and sleep disturbance]) 
and dependent variables of objective cognitive function (immediate and delayed memory, 
attention, executive function-working memory, and verbal fluency) and subjective 
cognitive function (attention) in older BCS.  
Results 
Participants included 335 older BCS in this study who ranged from 60 to 70 years 
of age and were on average 63.85 (SD 2.97) years old at the time of their breast cancer 
diagnosis and were on average 69.79 (SD 3.34) years old at the time of data collection. 
Table 3-1 reflects the demographic, medical and treatment characteristics of the older 
BCS in this sample in full detail. At the time of survey and neuropsychological 
assessment completion older BCS were on average 5.95 (SD 1.48) years post-diagnosis. 
At initial diagnosis, most of the older BCS had stage II breast cancer (n=227; 67.7%). 
The majority of the BCS included in this study were White (n=313; 93.4%), married 
(n=218; 65.1%), educated with at least some college (n=173; 51.6%), and had an income 
of less than $50,001 per year (n=194; 57.9%). All older BCS received chemotherapy as 
part of their initial treatment; the majority had a mastectomy (n=178; 53.1%) and 
radiation therapy (n=203; 60.6%) as part of their breast cancer treatment regimen. In 
addition, age, education, and race information from the NCCs, used for calculating 
dysfunction prevalence for each neuropsychological assessment, is included in Table 3-1. 
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NCCs (n=228) were on average 64.21 (SD 6.08) years of age, had on average 15.34 (SD 
2.84) years of education, and were mostly White (n=180; 80.3%).  
Table 3-2 presents descriptive information including mean, standard deviation 
(SD), potential and actual score range for the cancer-related symptoms (depressive 
symptoms, anxiety, fatigue, and sleep disturbance). For depressive symptoms, scores at 
or above 16 indicate depression. Overall, the mean for depressive symptoms in this 
sample is 8.73 (SD 7.83); however, 16.8% (n=56) of the older BCS did have depressive 
symptom scores at 16 or over indicating depression. For the other symptoms, anxiety, 
fatigue, and sleep disturbance, there are not validated cut scores to report, but descriptive 
information can be found in Table 3-2.  
Older BCS demonstrated cognitive dysfunction with levels ranging from mild (1 
SD), mild to moderate (1.5 SD), and moderate (2 SDs) below NCC for each 
neuropsychological assessment [126]. Table 3-3 depicts mean, standard deviation (SD), 
potential and actual score range, and the percentage of older BCS and NCCs within each 
level of cognitive dysfunction. Only dysfunction for older BCS will be described below. 
For immediate memory (AVLT), older BCS demonstrated significant dysfunction with 
27.8% (n=93) ‘mild’, 12.9% (n=43) ‘mild-moderate’, and 5.7% (n=19) ‘moderate’ 
dysfunction. For delayed memory (AVLT), older BCS demonstrated significant 
dysfunction with 19.2% (n=64) ‘mild’, 11.1% (n=37) ‘mild-moderate’, and 3.3% (n=11) 
‘moderate’ dysfunction. For attention (Digit Span-Forward), older BCS demonstrated 
significant dysfunction with 4.2% (n=14) ‘mild’ dysfunction, no older BCS in this 
sample scored 1.5 SD or 2 SDs below NCC. For executive function-working memory 
(Digit Span-Backward), older BCS demonstrated significant dysfunction with 9.9% 
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(n=33) ‘mild’, 2.1% (n=7) mild-moderate’, and 1.2% (n=4) ‘moderate’ dysfunction. For 
verbal fluency (COWA), older BCS demonstrated significant dysfunction with 40.4% 
(n=135) ‘mild’18.6% (n=62) ‘mild-moderate’, and 7.5% (n=25) ‘moderate’ dysfunction 
[126].  
Table 3-4 depicts the mean, standard deviation (SD), potential and actual score 
range, and the percentage of older BCS in each threshold for the subjective cognitive 
function using the Attention Function Index (AFI). Based on predetermined cut points, 
26% (n=87) of BCS reported poor to moderate attention function and the majority 70.8% 
(n= 237) reported effective attention function [71]. 
Pearson bivariate correlations were used to examine relationships between 
objective and subjective cognitive function measures (aim 2a) with full results depicted in 
Table 3-5. In bivariate analysis, subjective attention measured by the Attentional 
Function Index (AFI) was significantly correlated with objective cognitive functioning on 
two objective measures included in this study. Objective attention (Digit Span- Forward) 
and executive function-working memory (Digit Span- Backward) significantly correlated 
with the subjective attention (AFI; r=.15, p<0.01; r=.18 p<0.01), respectively. Objective 
immediate memory (AVLT), delayed memory (AVLT), and verbal fluency (COWA) 
were not significantly correlated with subjective attention (AFI). 
Separate multiple linear regression models were used to determine the 
relationships between independent variables of age, education, comorbidities, time since 
diagnosis, breast cancer stage, depressive symptoms, anxiety, fatigue, and sleep 
disturbance in relation to dependent variables of cognitive function including immediate 
and delayed memory, attention, executive function-working memory, verbal fluency, and 
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subjective attention. Table 3-6 displays the results of the regression analysis. The models 
for immediate memory [F(9,300)=2.59, adjusted r2=.04, p<.01], delayed memory 
[F(9,300)=1.98, adjusted r2=.03, p<.05], verbal fluency [F(9,300)=4.11, adjusted r2=.08, 
p<.001], and subjective attention [F(9,291)=26.54, adjusted r2=.43, p<.001] were 
statistically significant. Models with objective attention and executive function-working 
memory were not significant. Immediate Memory: The model explained 4% of the 
variance of immediate memory, with age (β=-0.14, p˂.05) and depressive symptoms (β=-
0.24, p˂.01) related to immediate memory. These results indicated that higher scores, 
older age and more depressive symptoms, were negatively related to immediate memory. 
Delayed Memory: The model explained 3% of the variance of delayed memory, with 
depressive symptoms (β=-0.23, p˂.01) related to delayed memory. These results 
indicated that higher scores, more depressive symptoms, was negatively related to 
delayed memory. Verbal Fluency: The model explained 8% of the variance of verbal 
fluency, with education (β=0.23, p˂.01) and depressive symptoms (β=-0.24, p˂.01) 
related to verbal fluency. These results indicated that higher scores, more education, was 
positively related to verbal fluency and higher scores, more depressive symptoms, were 
negatively related to verbal fluency. Subjective Attention: The model explained 43% of 
the variance of subjective attention, with education (β=0.10, p˂.05), depressive 
symptoms (β=-0.24, p˂.01), anxiety (β=-0.15, p˂.05), and fatigue (β=0.39, p˂.01) related 
to subjective attention. These results indicated that higher scores, more education and less 
fatigue, were positively related to subjective attention, and higher scores, more depressive 





Older BCS are a growing population with unique needs. Many older BCS 
experience cognitive dysfunction, which has been previously understudied. This study 
helps to elucidate some of the complexity of cognitive dysfunction in older BCS by 
examining relationship between objective and subjective cognitive dysfunction and 
factors associated with both subjective and objective cognitive dysfunction, while also 
highlighting the prevalence of cognitive dysfunction in this population.  
Older BCS in this study were noted to have clinically significant cognitive 
dysfunction on neuropsychological exam. Up to 18.6% of the older BCS demonstrated 
mild-moderate dysfunction (1.5 SD below the mean of NCCs) on at least one out of five 
neuropsychological assessments or cognitive domains. Immediate memory (AVLT) and 
verbal fluency (COWA) appeared to have the highest percentage of BCS with 
dysfunction. In addition, 26% (n=87) of older BCS reported moderate to poor subjective 
attention function (AFI) based upon published cut scores. The objective cognitive 
dysfunction results are similar to the literature [64]. In addition, subjective reports of poor 
to moderate dysfunction were somewhat higher than objective measures of dysfunction, 
which is also consistent with the larger BCS literature [103,104].  
Both objective and subjective cognitive assessments are important tools for 
assessing cognition in BCS, although previous literature has shown that the instruments 
do not consistently correlate [113,123]. In this study, subjective attention (measured by 
the AFI) was modestly correlated with two objective cognitive domains, objective 
attention (measured by the Digit Span-forward) and executive function-working memory 
(measured by the Digit Span- backward). This work importantly identifies the AFI as a 
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sensitive measure for self-reported cognitive dysfunction, specifically for attention and 
executive function-working memory. The AFI is a short, 13-item, self-report instrument, 
which has potential use for practice, where it could be used as a brief screening tool for 
older BCS, identifying those with cognitive concerns [71]. The AFI could provide 
healthcare providers glimpse into potential concerns of older BCS regarding attention and 
executive function-working memory. The use of the AFI in clinic setting would be cost 
and time effective and is feasible as a quick assessment tool providing less disruption 
than a full neuropsychological assessment. Attention and executive function-working 
memory are important cognitive domains for older adult’s independence and play a role 
in many daily activities such as driving, reading, and grocery shopping [127]. 
Although the models were not very explanatory regarding objective cognitive 
function (adjusted r2 =.03-.08), there were some important and significant findings. Most 
notably, depressive symptoms (measured by the CES-D) were significantly related to 
both objective (immediate memory, delayed memory, and verbal fluency) and subjective 
cognitive dysfunction (attention) in this study of older BCS. This finding is important 
because unlike previous BCS studies, depressive symptoms and objective cognitive 
dysfunction have often not been correlated [34,39,41,98,128,129].  
Depressive symptoms and cognitive dysfunction may significantly affect older 
BCS. Cognitive dysfunction can impede proper diagnosis and treatment or lead to 
underreporting of depressive symptoms in older adults [130]. In this sample, 16.8% 
(n=56) had depressive symptom scores ≥16, indicating clinically significant depressive 
symptoms [55,56,130]. Depressive symptoms may also affect cognitive functioning. In 
addition, depressive symptoms in older adults have been shown to be related to female 
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sex, cognitive dysfunction, and stressful life events [130]. Together these findings would 
indicate that older BCS may be a greater risk of both depressive symptoms and cognitive 
dysfunction [130]. This finding also highlights the importance of a comprehensive 
geriatric assessment in older BCS that includes the assessment of both depressive 
symptoms and cognitive dysfunction. Proper management of depression may also 
improve cognitive dysfunction; management of depressive symptoms part of the National 
Comprehensive Cancer Networks guidelines for cognitive dysfunction and important for 
clinical practice [33,42,130]. Overall, depressive symptoms are important, modifiable, 
amenable to treatment, and should not be overlooked in addressing the needs of older 
BCS. 
Other cancer-related symptoms are also important factors associated with 
cognitive dysfunction. In this study, depressive symptoms (as previously mentioned), 
anxiety, and fatigue were related to subjective cognitive dysfunction (attention). In this 
study, sleep disturbance was not significant in the model, although other studies have 
found significance [43,97]. Similar results regarding the association of these cancer-
related symptoms either as independent symptoms or as a psychoneurological symptom 
cluster have been noted in all age [131,129] and older BCS [23,24,39,43,100]. Tometich 
and colleagues (2019) examined the psychoneurological symptom cluster (depression, 
anxiety, fatigue, sleep disturbance and pain) and its relationship with cognitive 
functioning before systemic treatment, 12 months, and 24 months later in 319 older BCS. 
These researchers noted that older BCS with high levels of psychoneurological symptoms 
versus low psychoneurological symptoms was significantly related to greater objective 
and subjective cognitive dysfunction at baseline and 24 months later [43]. This work 
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supports a potential phenotype and is important for consideration in future research in 
older BCS.  Research addressing predictors, mechanisms, management of this 
psychoneurological symptom cluster to improve QoL and functional impairment in older 
BCS is warranted [43].  
Limitations  
There are some limitations that should be noted in this study. This study is limited 
in that it used existing cross-sectional data that prohibited both employing other measures 
that may be related to cognitive dysfunction as well as limited interpretation of the data to 
association vs. causal inferences. However, this study provides a foundation to better 
understand the complex and unique issue of cognitive dysfunction in older BCS. The 
majority of the participants in this study were non-Hispanic white and very well-
educated, which limits generalizability to the larger BCS population. In addition, only 
one aspect of subjective cognitive function was examined in this study, subjective 
attention measured by the AFI. Additional measures of subjective cognitive dysfunction 
could be useful when addressing the first aim examining the relationship between 
objective and subjective cognitive dysfunction. We ran multiple regression analyses with 
separate outcome variables increasing the risk for type I error; however, a power analysis 
was completed to ensure appropriate power. Overall, the model was not very explanatory; 
however, these findings do provide some insight into potentially important factors.  
Conclusion 
 This study identifies cognitive dysfunction as a significant concern for older BCS 
3-8 years post breast cancer diagnosis. The oldest BCS, with less education, and more 
depressive symptoms were most likely to have cognitive dysfunction. Finally, healthcare 
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providers should be aware of and assess for cognitive dysfunction in older BCS even 
years after diagnosis and treatment as it is clear cognitive dysfunction can still be a 










Age at breast cancer diagnosis, years  63.85 (2.97) n/a 
Time since diagnosis, years 5.95 (1.48) n/a 
Age at data collection, years 69.79 (3.34) 64.21 (6.08) 
Time duration initially treated for breast 
cancer, months 
8.02 (4.12) n/a 
Education, years 13.73 (2.53) 15.34 (2.84) 
 n (%) n (%) 
Race  
White 




































Table 3-2 Cancer-Related Symptoms and Measures - Mean (SD), Potential Range, and 
Actual Range 
 





Depressive symptoms (CES-D)  8.73 (7.83) 0-60 0-41 
Anxiety-State (STAI)  30.55 (9.56) 20-80 20-70 
Fatigue (FACT-F)  41.28 (9.31) 0-52 5-52 
Sleep Disturbance Subscale (PSQI) 1.33 (0.506) 0-3 0-3 
 
CES-D = Center for Epidemiological Studies Scale; STAI = State-Trait Anxiety 
Inventory – State and Trait subscales; FACT-F = Functional Assessment of Cancer 






























































N/A 10-76 40.4% 18.6% 7.5% 

























































N/A 0-75 14.7% 6.1% 1.2% 
 
AVLT=Rey Auditory Verbal Learning Test; COWA=Controlled Oral Word Association; 





























0-130 34-130 237 (70.8%) 77 (23%) 10 (3%) 
 





Table 3-5 Cognitive Measure Bivariate Correlations  
 
Variable (measure) (n=335) 1 2 3 4 5 6 
1. Immediate memory (AVLT) -      
2. Delayed memory (AVLT) .693** -     
3. Attention (Digit Span - 
Forward) 
.299** .238** -    
4. Executive function - working 
memory (Digit Span - 
Backwards) 
.294** .281** .676** -   
5. Verbal fluency (COWA) .240** .147** .177** .110* -  
6. Subjective attention (AFI) .085 .651 .151** .178** .101 - 
 
*p<.05; **p<.01; AVLT = Rey Auditory Verbal Learning Test; COWA = Controlled Oral 





Table 3-6 Regression Analysis Summary for Demographic, Medical, and Treatment 
















Age =-.14*      
Education     =.23** =.10* 
















Anxiety      =-.15* 






F 2.59** 1.98* .577 .739 4.11** 26.54** 
R2 .07 .06 .017 .022 .11 .45 








 Comorbidities are common among older adults, the majority (80%) have at least 
one comorbid condition, with the most common comorbidities being cardiovascular 
disease, obesity, diabetes, and arthritis [132]. In addition, individuals who have had 
cancer tend to report more comorbidities than those with no history of cancer [133]. 
Cognitive dysfunction, a common cancer-related symptom experienced by breast cancer 
survivors (BCS), has been associated with comorbidities in the larger aging literature 
[134]. The relationship between comorbidities and cognitive dysfunction in older BCS 
specifically has begun to be addressed in the literature as well, although findings have 
been mixed [23,24,34,39,41,98,135]. With the high probability that older BCS will most 
likely also have other comorbid conditions, and the commonality of cognitive 
dysfunction among older BCS, this is an important area for further investigation.  
Comorbidities and cognitive dysfunction have also been related to decreased 
levels of physical functioning [136] and decreased quality of life (QoL) in older adults 
[137,138]. Physical functioning is important to living well and is especially important for 
older adults and living independently [139]. Decreased physical functioning can lead to 
the need for hospitalization, long-term care, and premature death [139]. QoL is important 
to older adults, with health, including symptoms, and ability identified as most important 
[140]. In general, decreased or poor physical functioning and QoL and have far reaching 
implications and impact upon the lives of older adults in general. These relationships 
have begun to be investigated in older BCS; however, there is limited data and the studies 
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completed previously have focused on older BCS in treatment and up to 2 years post-
treatment.  
Therefore, the purpose of this study was to examine comorbidities, objective 
cognitive function, and subjective cognitive function and their relationship with physical 
functioning and QoL in older BCS 3-8 years post-diagnosis, controlling for age and 
education. This work is important for older BCS, their families, and caregivers as well as 
healthcare providers, including primary care providers or geriatricians who will be seeing 
older BCS and should be aware of these issues and their implications.  
Methods 
For this secondary data analysis study, cross-sectional data were leveraged from a 
BCS study aimed at examining QoL in younger versus older BCS (American Cancer 
Society RSGPB-04-089-01, PI: V. Champion) [52]. Full details regarding recruitment, 
eligibility criteria, and data collection can be found in chapters 1 and 3.  
Population and Data Collection 
This study focuses on older BCS who were 60 years of age and older, 3-8 years 
post-diagnosis for stage I-III breast cancer without recurrence and treated with 
chemotherapy. Eligible older BCS were recruited from one of the 97 Eastern Cooperative 
Oncology Group (ECOG) cites and Indiana University (IU). IRB approval was obtained 
by IU and all participating ECOG sites. Once verbal informed consent was obtained for 
interested BCS, written consents and questionnaires were mailed to BCS. Participants 
then set a date for their neuropsychological assessment, which was performed by trained 
staff via the telephone. Participants received $50 total for completing both the survey and 




Demographic. Standard demographic data (i.e. age, race, ethnicity, marital status, 
education) were collected via an investigator-initiated self-report questionnaire. 
Comorbidities. Comorbidities were collected via self-report survey where BCS 
responded yes or no to a list of potential comorbid conditions including: arthritis, heart 
disease or heart problem, high blood pressure or hypertension, stroke, serious breathing 
disease or problem, kidney disease or problem, high cholesterol, diabetes, leukemia or 
cancer (not breast cancer), anxiety/panic disorders, depression, eating disorders, hip 
fracture, surgical replacement of joint, problem with urinary control, eye problems (other 
than corrective lenses), hearing problems, Other problem – please specify, and none. For 
the analyses in this study the total number of comorbidities were reported. 
Objective Cognitive Function. Objective cognitive function including immediate 
memory, delayed memory, attention, executive function-working memory, and verbal 
fluency were measured using valid and reliable neuropsychological assessments that have 
been used in BCS. The Rey Auditory-Verbal Learning Test (AVLT) was used to assess 
immediate and delayed memory by completing a 15-word learning task, where the tester 
lists 15 words and the participant must try to remember and recite them [63,65,66]. For 
both immediate and delayed memory, higher scores indicating better functioning 
[63,65,66]. The Wechsler Adult Intelligence Scale (WAIS) - Digit Span Forward and 
Backward were used to assess attention and executive function-working memory, 
respectively. For the Digit Span test, the tester lists numbers in a string and the 
participant must recite them in order for the Forward test and must recite the numbers in 
reverse order for the Backward test [67,68]. For both the Digit Span-Forward and 
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Backward, higher scores indicating better functioning [67,68]. The Benton Controlled 
Oral Word Association Test (COWA) was used to assess verbal fluency by giving the 
participant a letter and 1-minute to produce as many words as possible that begin with 
that letter (excluding proper nouns) [69,70,124]. Potential and actual score ranges for this 
test will vary, however higher scores indicating better functioning [69,70,124].  
Subjective Cognitive Function. The Attentional Function Index (AFI) is a 13-
item scale was used to assess subjective attention at the present time. Potential scores can 
range from 0-130, with higher scores indicate better functioning [71]. In this study, the 
AFI Cronbach alpha was .80 indicating good reliability. 
Physical Functioning. The physical functioning (PF-10) is a subscale of the 
Medical Outcomes Study 36-item Short Form Health Survey (SF-36). The PF-10 is 10-
items and measures the participants perceived limitations of physical functioning during 
the past four weeks with higher scores indicating less limitation or disability [72]. The 
PF-10 is an established measure of physical functioning that has shown reliability and 
validity in various populations including cancer patients [72]. In this study, the Cronbach 
alpha was .89 indicating good reliability. 
Quality of Life. The Index of Well-Being-Survivor (IWB) instrument measures 
overall QoL including life satisfaction and subjective well‐being [74]. This is a 9-item 
measure developed to assess specific concerns of long-term cancer survivors with higher 
scores indicating higher/better QoL. The IWB scale has established reliability and 
validity and has been widely used in cancer patients including BCS [52,73]. In this study, 




Data Analysis  
Descriptive statistics were computed to describe the sample and ensure data 
quality, identify out of range values, and evaluate the assumptions of statistical tests 
including normality and intercorrelation of independent variables. Separate multiple 
linear regression models were used to examine the relationships between the independent 
variables of age (years age at neuropsychological assessment), education (total number of 
years of education), comorbidities (total number of self-reported comorbidities), 
objective cognitive function (immediate memory, delayed memory, attention, executive 
function-working memory, and verbal fluency) and subjective cognitive function 
(attention) and dependent variables of physical functioning (PF-10) and QoL (IWB) in 
older BCS. Significance level was set at 0.05. SPSS statistical software, version 26 was 
used for all data analysis. 
Results 
Older BCS (n=335) who participated in this study were 3-8 years post-diagnosis 
(M 5.95, SD 1.48) and 60-70 years of age (M 63.85, SD 2.97). On average long-term 
older BCS reported having 3 (SD 1.81) comorbid conditions, with total number of 
comorbid conditions ranging from 0-12 throughout this sample. The most common 
comorbidities reported were hypertension (n=192; 57.3%), arthritis (n=186; 55.5%), and 
high cholesterol (n=151; 45.1%). Table 4-1 depicts a more thorough breakdown of 
comorbidities reported by long-term older BCS in this study. Chapter 3 gives greater 
detail on the sample characteristics of this study including education, race, marital status, 
income, and treatment factors (radiation, surgery). 
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Descriptive information about the outcome variables/measures of physical 
functioning and QoL including, mean, standard deviation, potential score range, and 
actual score range for this study can be found in Table 4-2. Actual physical functioning 
scores ranged from 5-100, with older BCS in this sample reporting scores of 70.71 (SD 
22.94) on average. Actual QoL scores ranged from 8.85-14.7, with older BCS in this 
sample reporting scores of 10.03 (SD 2.31) on average. For both of these scales, higher 
scores indicate better functioning.  
The regression analyses examining age, education, comorbidities, objective 
cognitive function and subjective cognitive function and their relationship with physical 
functioning and QoL in older BCS are displayed fully in Table 4-3 and described in detail 
below.  
Physical Functioning 
Immediate Memory: The model including age, education, comorbidities, and 
immediate memory was significant [F(4,321)= 27.15, adjusted r2=.24; p<.001]. The 
model explained 24% of the variance of physical functioning, with education (β=.12, 
p˂.05) and comorbidities (β=-0.48, p˂.001) related to physical functioning. These results 
indicated that higher scores, more education, was positively related to physical function 
and more comorbidities was negatively related to physical function. Delayed Memory: 
The model including age, education, comorbidities, and delayed memory was significant 
[F(4,321)= 26.95, adjusted r2=.24; p<.001]. The model explained 24% of the variance of 
physical functioning, with education (β=.12, p˂.05) and comorbidities (β=-0.48, p˂.001) 
related to physical functioning. These results indicated that higher scores, more 
education, was positively related to physical function and more comorbidities was 
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negatively related to physical function. Attention: The model including age, education, 
comorbidities, and attention was significant [F(4,321)= 26.76, adjusted r2=.24; p<.001]. 
The model explained 24% of the variance of physical functioning, with education (β=.13, 
p˂.05) and comorbidities (β=-0.48, p˂.001) related to physical functioning. These results 
indicated that higher scores, more education, was positively related to physical function 
and more comorbidities was negatively related to physical function. Executive Function-
Working Memory: The model including age, education, comorbidities, and executive 
function-working memory was significant [F(4,321)= 26.76, adjusted r2=.24; p<.001]. 
The model explained 24% of the variance of physical functioning, with education (β=.13, 
p˂.05) and comorbidities (β=-0.48, p˂.001) related to physical functioning. These results 
indicated that higher scores, more education, was positively related to physical function 
and more comorbidities was negatively related to physical function. Verbal Fluency: The 
model including age, education, comorbidities, and verbal fluency was significant 
[F(4,321)= 26.76, adjusted r2=.24; p<.001]. The model explained 24% of the variance of 
physical functioning, with education (β=.13, p˂.05) and comorbidities (β=-0.48, p˂.001) 
related to physical functioning. These results indicated that higher scores, more 
education, was positively related to physical function and more comorbidities was 
negatively related to physical function. Subjective Attention: The model including age, 
education, comorbidities, and subjective attention was significant [F(4,312)= 33.81, 
adjusted r2=.29; p<.001]. The model explained 29% of the variance of physical 
functioning, with education (β=.11, p˂.05), comorbidities (β=-0.42, p˂.001), and 
subjective attention (β=.23, p˂.001), related to physical functioning. These results 
indicated that higher scores, more education and better subjective attention, were 
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positively related to physical functioning and more comorbidities was negatively related 
to physical functioning. 
Quality of Life 
 The regression analysis models for age, education, comorbidities and objective 
cognitive measures (immediate memory, delayed memory, attention, executive function-
working memory, and verbal fluency) and QoL were not significant. However, the model 
for subjective attention was significant. Subjective Attention: The model including age, 
education, comorbidities, and subjective attention (AFI) related to QoL was significant 
[F(4,310)= 12.59, R2=.14, adjusted r2=.13; p<.001]. The model explained 13% of the 
variance of QoL, with subjective attention (β=.39, p˂.001) significantly related to QoL. 
These results indicated that higher scores, better subjective attention, was positively 
related to QoL. 
Discussion 
 Many older BCS experience multiple comorbidities as well as cognitive 
dysfunction following cancer diagnosis and treatment. Both of these can have negative 
consequences or implications for the older BCS, including decreased physical 
functioning and QoL, which in turn, hold their own negative implications. This study aids 
in illustrating some of the implications for physical functioning and QoL in older BCS by 
examining the associations between comorbidities and cognitive dysfunction with 
physical functioning and QoL.  
 The findings of this study highlight the relationship between comorbidity and 
physical functioning within the regression models. Interestingly, comorbidities were not 
related to QoL in any of the regression analysis models, which contrasts the aging and 
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cancer literature where comorbidities have been linked to QoL [137,138]. The most 
common comorbidities for the older breast cancer survivors in this study were similar to 
that of the general older adult population, hypertension and arthritis. Approximately 94% 
(n=314) of the older BCS in this study, had at least one comorbid condition, as compared 
to 80% reported on average in the general older adult population [132]. This validates 
that individuals who have had cancer are more likely to have comorbidities than those 
without a history of cancer diagnosis and treatment [133]. Increased comorbidities and 
decreased physical functioning can have serious consequences in older adults [139]. In 
addition, cardiovascular disease, a common comorbidity, has been identified as the 
leading cause for morbidity in older BCS [142]. These findings taken together highlight 
the importance of managing comorbid conditions by healthcare providers treating older 
BCS. 
 Subjective cognitive dysfunction (subjective attention), measured by the AFI in 
this study was significantly related in the model to physical functioning. In studies in 
older adults, subjective cognitive dysfunction has been shown to be correlated with 
subjective reports of physical functioning impairment. In a study regarding trajectories of 
subjective cognitive decline, Mandelblatt and colleagues (2016) found that accelerated 
cognitive decline was associated with a decline in physical functioning in older BCS [23]. 
However, unlike subjective cognitive function, objective measures of cognitive function 
were not specifically related to physical functioning in any of the models. Similar 
findings have been noted in previous studies in older BCS that have examined this 
relationship [34,39,41]. Lange et al. (2014) found that in 123 older BCS with a mean age 
of 70 years old, objective cognitive dysfunction was not related to performance status, 
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which they hypothesized was likely due to a large proportion of BCS being in very good 
general health [39]. More research is needed to fully understand the link between 
cognitive dysfunction and physical functioning in older BCS.  
Subjective cognitive dysfunction (subjective attention), was also significantly 
related in the model to QoL. Importantly, this finding suggests that perceived or 
subjective cognitive dysfunction has implications to QoL. Similar findings have been 
noted in all age BCS [73] and older BCS [39,100]. However, objective measures of 
cognitive function were not related to QoL in any of the models. Often times objective 
measures of cognitive dysfunction do not correlate with subjective reports of QoL. 
Similarly, Biglia and colleagues (2012) found that objective cognitive dysfunction was 
not related to QoL in 40 all age BCS [128]. In contrast, Lange et al. (2016) found that 
objective cognitive decline was associated with the QoL subscale of the Functional 
Assessment of Cancer Therapy, Cognitive Scale (FACT-Cog) in 119 older BCS [34]. 
This relationship may be the result of asking specifically about QoL concerns related to 
cognitive dysfunction [34]. More research is needed to generate data on the relationship 
between cognitive dysfunction and QoL to fully understand the impact cognitive 
dysfunction has on QoL in older BCS and to begin to develop interventions to alleviate 
issues in older BCS.  
Limitations 
Although this study provides new information regarding comorbidity, cognitive 
functioning, physical functioning, and QoL in older BCS, the study does have limitations 
that should be addressed. The data for this study is cross-sectional in nature, providing a 
snapshot of the variables at one point in time, which limits the ability to determine casual 
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relationships.  A prospective, longitudinal study may have provided more insight into 
how these relationships work. We ran multiple regression analyses with separate outcome 
variables increasing the risk for type I error; however, a power analysis was completed to 
ensure appropriate power. In addition, the majority of the older BCS in this study are 
white (93%), therefore all races are not represented in this study, which limits 
generalizability to the overall BCS population. Future studies should focus on recruiting 
more racially diverse samples.  
Conclusion 
 Overall, older BCS with fewer years of education, more self-reported 
comorbidities, and worse subjective cognitive function had worse physical functioning. 
As for QoL, older BCS in this study who reported better subjective cognitive function 
reported better QoL. These findings are important when considering survivorship care for 
older BCS, including maintenance of physical functioning and QoL, which can impact 




Table 4-1 Self-reported Comorbid Conditions  
 
Average Number of Comorbid Conditions  
M (SD) 
(n=335) 
 3.06 (1.81) 
Total Number of Comorbid Conditions % (n) 
0  6.3% (21) 
1-2 31.9% (107) 
3-4 39.4% (132) 
≥5 22.4% (75) 
Comorbid Condition % (n) 
High blood pressure or hypertension 57.3% (192) 
Arthritis 55.5% (186) 
High cholesterol 45.1% (151)  
Eye problems (other than corrective lenses) 24.8% (83) 
Depression 17.3% (58) 
Diabetes 16.4% (55) 
Heart disease or heart problem 14% (47) 
Other  13.4% (45) 
Surgical replacement of joint 12.8% (43) 
Problem with urinary control 12.2% (41) 
Anxiety/panic disorders 9.6% (32) 
Serious breathing disease or problem 8.1% (27) 
Hearing problems 6.9% (23) 
Stroke 3.3% (11)  
Leukemia or cancer (not breast cancer) 3.3% (11) 
Kidney disease or problem 2.4% (14) 
Eating disorders 1.2% (4) 
Hip fracture 0.9% (3) 
 
*(descending order from most prevalent to least prevalent condition)  
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Table 4-2 Outcome Variables and Measures - Mean (SD), Potential Range, and Actual 
Range 
 





Physical Functioning (PF-10) 70.71 (22.94) 0-100 5-100 
QoL (IWB) 12.03 (2.31) 2.1-14.7 2.85-14.7 
 





Table 4-3 Regression Analysis Summary for Age, Education, Comorbidities, Cognitive 








Age (age at data collection)   
Education (number of years) =.12*  
Comorbidities (self-reported 
total number of comorbid 
conditions) 
=-.48**  
Immediate Memory (AVLT)   
F 27.15** .61 
R2 .25 .01 
Adjusted r2 .24 -.01 
Delayed Memory 
 




Age (age at data collection)   
Education (number of years) =.12*  
Comorbidities (self-reported 
total number of comorbid 
conditions) 
=-.48**  
Delayed Memory (AVLT)   
F 26.95** .67 
R2 .25 .01 
Adjusted r2 .24 .00 
Attention  
 




Age (age at data collection)   
Education (number of years) =.13*  
Comorbidities (self-reported 








F 26.76** 1.19 
R2 .25 .02 
Adjusted r2 .24 .00 
Executive Function-Working Memory  
 




Age (age at data collection)   
Education (number of years) =.13*  
Comorbidities (self-reported 







F 26.76** 1.52 
R2 .25 .02 
Adjusted r2 .24 .01 
Verbal Fluency 
 




Age (age at data collection)   
Education (number of years) =.13*  
Comorbidities (self-reported 
total number of comorbid 
conditions) 
=-.48**  
Verbal Fluency (COWA)   
F 26.76** .70 
R2 .25 .01 
Adjusted r2 .24 .00 
Subjective Attention 
 




Age (age at data collection)   
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Education (number of years) =.11*  
Comorbidities (self-reported 
total number of comorbid 
conditions) 
=-.42**  
Subjective Attention (AFI) =.23** =.39** 
F 33.81** 12.59** 
R2 .30 .14 
Adjusted r2 .29 .13 
 
*p<.05; **p<.01; PF-10=Physical functioning – 10 sub-scale; IWB=index of well-being; 
AVLT=Rey Auditory Verbal Learning test; COWA=Controlled Oral Word Association 







The purpose of this dissertation study was to add to the literature and body of 
knowledge regarding cognitive dysfunction in older breast cancer survivors (BCS) and to 
fully characterize cognitive dysfunction in older BCS. Chapter 1 was an introduction, 
highlighting the background, significance, and conceptual framework that laid the 
foundation for the subsequent chapters. Chapter 2 described an integrative review of 12 
studies previously published regarding cognitive dysfunction in older BCS. Information 
from that review provided additional background and support for the following chapters. 
Chapter 3 and 4 described the quantitative descriptive studies, which leveraged 
previously collected cross-sectional data to examine relationships. Chapter 3 specifically 
examined the relationships between objective cognitive function and subjective cognitive 
function, and the relationships between demographic factors, medical factors, treatment 
factors, and cancer-related symptoms and objective and subjective cognitive function, in 
older BCS. Chapter 4 examined the relationships between comorbidities, objective 
cognitive function, and subjective cognitive function and physical functioning and quality 
of life (QoL), in older BCS. The present chapter will summarize the key dissertation 
findings, describe and address the strengths and limitations of the dissertation study, and 
provide implications for future research and practice regarding cognitive dysfunction in 






Summary of Key Findings 
Chapter 2 
 The purpose of chapter 2 was to identify and synthesize the current evidence 
regarding cognitive dysfunction in older BCS, including the prevalence and factors 
associated with objective and subjective cognitive dysfunction. The purpose was 
addressed by completing an integrative review using the Whittemore and Knafl method 
[76]. Twelve studies, which focused on cognitive dysfunction in older BCS, were 
included in the review. Cognitive dysfunction among older BCS was common both prior 
to and following treatment, although most of the studies did not extend beyond 2 years 
into survivorship. Older BCS experienced cognitive dysfunction as measured by both 
objective neuropsychological assessments and subjective (self-report) instruments. In 
addition, approximately half of the older BCS experienced cognitive decline from pre-to 
post-treatment regardless of the cognitive measure employed. The domains most 
impacted were memory, executive function, and processing speed. Throughout the 
studies in the review, both objective and subjective cognitive dysfunction was associated 
with age, comorbidities, chemotherapy receipt, sleep, psychoneurological symptom 
cluster, frailty, and QoL. Many of the factors associated with cognitive dysfunction are 
specific to the aging population and/or can be compounded in the aging population and 
could be detrimental to QoL and independent living. This integrative review identified 
gaps in the current literature about cognitive dysfunction in older BCS and provided a 





Chapter 3  
The purpose of chapter 3 was to examine the relationships between subjective and 
objective cognitive function and factors associated with both subjective and objective 
cognitive function in older BCS, to address this gap in the literature identified in chapter 
2. The purpose was addressed by a cross-sectional descriptive study, which leveraged 
previously collected data from older BCS (n=335). Cognitive dysfunction was prevalent 
with up to 18.6% of older BCS experiencing mild-moderate dysfunction (1.5 standard 
deviations below the mean of non-cancer controls) in at least one cognitive domain. Poor 
to moderate subjective attention function was reported by 26% of older BCS in this 
sample. Pearson bivariate correlations were used to examine relationships between 
objective and subjective cognitive function measures. Subjective attention measured by 
the Attentional Function Index (AFI) was significantly correlated with objective 
cognitive functioning on two measures, objective attention (Digit Span- Forward) and 
executive function-working memory (Digit Span- Backward) (p<0.01). Separate linear 
regression models were used to determine the relationships between independent 
variables of demographic factors (age and education),  medical factors (comorbidities), 
and treatment factors (time since diagnosis and breast cancer stage), and cancer-related 
symptoms (depressive symptoms, anxiety, fatigue, and sleep disturbance) in relation to 
dependent variables of cognitive function including immediate memory, delayed 
memory, attention, executive function-working memory, verbal fluency, and subjective 
attention. Although the models were not very explanatory, the models for immediate 
memory (p<.01), delayed memory (p<.05), verbal fluency (p<.001), and subjective 
attention (p<.001) were statistically significant; whereas, objective attention and 
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executive function-working memory were not significant. Across all of the significant 
models depressive symptoms was most notable and was significantly related to both 
objective and subjective cognitive functioning. In addition, age, education, anxiety and 
fatigue also were significant. These findings indicate that depression in older BCS is an 
exceedingly important factor related to cognitive functioning and should be 
acknowledged in future research and care for older BCS.  
Chapter 4 
 The purpose of chapter 4 was to examine comorbidities, objective cognitive 
function, and subjective cognitive function and their relationship with physical 
functioning and QoL in older BCS, controlling for age and education. The purpose was 
addressed by utilizing cross-sectional data previously collected data from older BCS 
(n=335). Separate linear regression models were used to examine the relationships. All of 
the models for physical functioning were significant with less education, more 
comorbidities, and worse subjective attention being related to decreased physical 
functioning, objective cognitive function was not significant in the models. One model 
was significant for QoL, with only worse subjective attention being related to worse QoL. 
Overall, in this chapter, increased number of self-reported comorbidities and poorer 
subjective attention function were most important and should be incorporated in future 
research and practice when investigating or assessing for issues regarding physical 
functioning and QoL.  
Strengths and Limitations 
There are many strengths of this dissertation. Multiple research priorities are 
addressed, including a focus on symptom science from the National Institute of Nursing 
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Research’s (2017) strategic plan [44]. Additionally, this study addresses aging, cancer, 
and cognition which has been identified as a priority by the Cancer and Aging Research 
Group, the International Cancer and Cognition Task Force, the National Institute on 
Aging, the National Cancer Institute, and the Oncology Nursing Society [45-47]. A 
thorough examination of the current literature provided the background in which to base 
the dissertation study. The requisite foundation to characterize cognitive dysfunction in 
older BCS, and ultimately support evidence-based intervention development to mitigate 
cognitive dysfunction is provided in the findings. This study was innovative and unique 
as it leveraged a large, nationwide, underserved, and growing population of older (60 
years of age and older) BCS who are 3-8 years post diagnosis, who have been historically 
excluded from most research. Most previous research regarding cognitive dysfunction in 
older BCS has been limited to up to 2 years post-treatment. In addition, both objective 
and subjective measures of cognitive function were used and the relationship between 
these measures was examined, which is needed in older BCS. Overall, this research 
advances the science and is a first step toward identifying those at greatest risk for 
cognitive dysfunction among older BCS.  
There are several limitations to this study that must be considered. The cross-
sectional data limits data analysis to association and no causal relationships can be made. 
We ran multiple regression analyses with separate outcome variables increasing the risk 
for type I error; however, a power analysis was completed to ensure appropriate power. 
The majority of the participants in this study were non-Hispanic white and mostly well-
educated, which is not representative of the overall older BCS population. In addition, in 
using already collected data, other associated factors or potential consequences for this 
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analyses that may be of interest in this older BCS population (i.e. independent activities 
of daily living, frailty, objective measures of physical functioning, etc.) were not able to 
be explored. However, this study is an important step in understanding the complex 
problem of cognitive dysfunction in older BCS, addresses gaps in the current knowledge, 
and significantly adds to the body of literature.  
Implications 
This dissertation advances the knowledge regarding cognitive dysfunction in 
older BCS. Findings from this dissertation present implications for both research and 
practice. Future research must focus on better understanding the intersection between 
depression and cognitive dysfunction (performance and self-report) in older BCS 
specifically. In addition, older adults with a history of cancer often have multiple 
comorbidities. In this study, increased number of comorbidities was related to decreased 
physical functioning in older BCS, which also warrants further research. Subjective 
cognitive dysfunction (attention) was related to multiple other cancer-related symptoms 
(depressive symptoms, anxiety, and fatigue), as well as, physical functioning and QoL. 
Subjective attention could be an indicator of problems that could limit functional ability 
and well-being in older BCS, with negative implications that could lead to other 
untoward outcomes such as hospitalization, need for long-term care, and potentially even 
morbidity and mortality [139]. More research regarding the intersection of aging, cancer, 
comorbidities and cognitive dysfunction is needed for this growing population of older 
BCS. In addition, future research should move beyond characterizing cognitive 
dysfunction and focus on evidence-based interventions for cognitive dysfunction 
incorporating the unique needs of older BCS. 
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This topic and dissertation study also unearthed implications for practice 
regarding the assessment and care of older BCS and cognitive dysfunction. Although 
further study is needed, one important finding is the relationship between objective 
measures of attention and executive function-working memory and subjective attention. 
The AFI may be a valuable tool to screen or initially assess for cognitive dysfunction in 
older BCS. The AFI is a brief tool that could be administered by healthcare providers in a 
clinic setting and assist clinicians in identifying patients, which may require follow-up 
neuropsychological assessment. In addition, assessment, surveillance, and management 
of multiple comorbid conditions, especially depression, in older BCS is of particular 
importance for survivorship care and primary care of older adults who have a history of 
cancer. As noted, in this study depression may have ramifications related to cognitive 
dysfunction. Depression may be amenable to standardized treatment and if treated 
effectively could also potentially ameliorate cognitive dysfunction in older BCS [33]. In 
addition, the total number of comorbid conditions was related to physical functioning and 
is another area for clinicians to direct close attention. A thorough geriatric assessment 
should be a key component of the cancer care continuum for older BCS [81,82,118]. 
Cognitive dysfunction before, during, and after breast cancer diagnosis and treatment 
should be a target for assessment and treatment for healthcare providers, especially in 
older BCS. 
Conclusions 
Cognitive dysfunction is a common concern among older BCS. Findings from this 
study are important and can contribute to effective symptom management of older BCS 
as the results deepen the understanding of cognitive dysfunction in older BCS. This is an 
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important descriptive study and foundational knowledge for being able to design 
interventions to alleviate or mitigate cognitive dysfunction and its negative consequences 
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